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Cancer is caused by random, accumulated gene mutations (for example, to the 
tumour suppressor p53 and PTEN genes) that lead to dysregulated cell growth and 
proliferation and to invasion and metastasis. Current treatments include 
chemotherapy, radiotherapy and surgery, but these can be insufficient. Novel 
therapies are needed, including the designing of adenoviruses (Ads) to target and 
kill cancer cells.  
 Loss of the p53 gene product in cancer cells has been previously exploited to 
confer conditional replication of certain mutant Ads in cancer cells without affecting 
normal cells. p53 activates PTEN transcription and the PTEN protein is stabilised by 
p53. PTEN could present another promising target to enable cancer-cell specific 
targeting of Ad-based therapies.  
Previous work in the Blair lab that led up to this project showed that both PTEN 
mRNA and protein were reduced by approx. 50% in Ad5-infected human cells.  In 
this project, the activity of the PTEN promoter was analysed during Ad5 infection of 
cells in which the normal p53 genes were either present or absent (mediated by 
targeted deletion). Using dual luciferase assays that measure the activity of a 
transfected PTEN promoter, it was established that there was no significant 
difference in PTEN promoter activity between Ad5-infected or mock-infected cells 
and that the presence or absence of p53 did not affect PTEN promoter activity in 
Ad5-infected cells. This suggests that any reduction in PTEN mRNA that occurs 
during Ad5 infection is mediated at a post-transcriptional level. In addition, Ad5 was 
previously shown in the Blair lab to be restricted for growth in a glioblastoma cell 
line, U87MG, which is PTEN-null. Here, PTEN-expressing derivatives of U87MG 
were generated by retroviral transduction. These cell lines were characterised in 
preparation for detailed comparative studies on Ad5 replication and killing of 
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2.1. Subversion of host cell signalling pathways by viruses 
Viruses are pathogens which must subvert the signalling pathways of the host cell to 
benefit their own replication. To enable viral replication, viral proteins target host 
proteins to alter the signalling pathways and inhibit the immune response. Of 
particular interest in this study is the interaction between viruses and tumour 
suppressor proteins and their pathways.  
Tumour suppressor proteins (TSPs) are involved in regulating cell processes 
including induction of apoptosis, inhibition of cell growth and DNA damage repair. 
Loss of function of TSPs contributes to cancer progression1. There is also some 
debate as to whether some tumour suppressor proteins may also indirectly have 
anti-viral functions2. In targeting tumour suppressor proteins, viruses are able to 
overcome cell cycle control and DNA damage repair mechanisms to alter the host 
cellular environment and make it more conducive to viral replication.  
In targeting tumour suppressor proteins, some viruses become mediators of 
oncogenesis. An example of this is high-risk human papillomavirus (HPV) types 16 
and 18, which are associated with a large majority of human cervical cancers3. 
These oncoviruses are useful for studying the interactions between viral proteins 
and TSPs. Many oncoviruses functionally deactivate the TSP p53, which leads to 
deregulation of apoptotic, DNA stability and cell proliferation pathways4. P53 exerts 
its tumour suppressor function as a transcription factor of genes involved in both 
intrinsic and extrinsic pathways of apoptosis5. Different viruses have evolved 
different mechanisms to target p53, to prevent apoptosis and thus permit viral 
replication. For example, the Hepatitis B virus protein HBx directly binds to p53 to 
sequester it in the cytoplasm, inhibiting its nuclear function. Additionally, HBx causes 
the overexpression of lncRNA HUR1, which interacts with p53 to promote cell 
proliferation by inhibiting the transcriptional regulation of p21 and Bax4.  
The HPV oncoprotein E6 contributes to transformation of the host cell by 
complexing with a ubiquitin ligase, E6AP, which polyubiquitinates p53. This leads to 
the ubiquitin-proteasome mediated degradation of p534.  
P53 is not the only tumour suppressor protein targeted during viral infection. pRb is 






SV40, and Adenoviruses6. To exert control of the cell cycle, pRb forms a complex 
with E2F family members, which initiate transcription when unbound. pRb also 
recruits chromatin remodelling factors including histone deacetylase 1 to repress 
E2F-dependent transcription6. During cell cycling, pRb is phosphorylated by cyclin-
dependent kinases which releases E2F and activates transcription of S-phase 
genes, thus overcoming the G1 to S-phase checkpoint.  
DNA tumour virus oncoproteins often contain an LxCxE motif, which is necessary for 
binding to the pocket region of pRb and other Rb family members, such as p105. 
The high-risk HPV oncoprotein E7 adopts this mechanism of pRb targeting, binding 
the hypophosphorylated form of pRb, preventing the formation of pRb-E2F 
complexes and enabling cell cycle progression to the S-phase6. 
Similarly, the Adenovirus E1A proteins also bind to the pocket region of pRb via an 
LxCxE motif, which displaces factors such as HDAC1 from pRb as well as inhibiting 
pRb-E2F complex formation6. E1A also recruits cellular histone acetyltransferase 
p300 into a complex with pRb, leading to acetylation of the pRb C-terminus. 
Acetylation of pRb results in increased interaction with the ubiquitin ligase MDM2, 
and subsequent ubiquitin-proteasome mediated degradation of pRb6.  
Adenoviruses also target p53 via the E1B-55K protein and E4ORF6 gene product. 
E1B-55K binds p53 near the N-terminus, and E4orf6 near the C-terminus, to prevent 
the transcriptional activity of the tumour suppressor. The E1B-55K/E4Orf6 binding is 
also responsible for the ubiquitin-proteasome mediated degradation of p53 by a 
Cullin-containing E3 ligase complex7. 
In addition to p53 and pRb, Adenovirus infection also modulates the tumour 
suppressor protein promyelocytic leukaemia protein (PML). PML regulates cell 
growth and apoptosis by numerous different mechanisms. PML is necessary for the 
activation of cyclin-dependent kinase inhibitor gene p21WAF1/CIP1 by retinoic acid8, 
and isoform PML-4 negatively effects the PI3K pathway by inhibiting mTOR and 
activating PTEN, as well as positively regulating the tumour suppressor p53 by 
promoting p53 acetylation and phosphorylation9. PML is also involved in regulating 
the localisation of the tumour suppressor PTEN by opposing the action of USP7, a 
deubiquitinylating enzyme that is associated with nuclear exclusion of PTEN10. PML 
function is frequently disrupted in virus infection, and in Ad infection, the PML bodies 






responsible for the structural change to the PML bodies, and E1A also co-localises 
to the PML bodies, through its LxCxE motif12. 
As adenovirus infection is reported to dysregulate p53, pRb and PML, it is possible 
that other tumour suppressor proteins may also be involved during infection. This 
project will focus on the role played by the tumour suppressor PTEN during Ad5 
infection. 
 
2.2. PTEN function 
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a dual 
specificity protein and lipid phosphatase that primarily dephosphorylates 
phosphatidylinositol phosphates at the 3’ position of the inositol ring13. It shows 
particular affinity for phosphatidylinositol-3,4,5-triphosphate (PIP3), and as such, 
acts as a negative regulator of phosphoinositol-3-kinase (PI3K), which 
phosphorylates phosphatidylinositol-4,5-bisphosphate to form PIP313 (Figure 1).  
In acting as a negative regulator of PI3K activity, PTEN aids the fine-tuning of 
downstream PI3K signalling, which includes protein kinase B (PKB, also known as 
AKT) and phosphoinositide dependent kinase 1 (PDK1). Further downstream 
effectors of these pathways include the Forkhead (FoxO) transcription factors, the 
mammalian target of rapamycin (mTOR) complex 1, cyclin D1 and others involved in 
key cellular processes such as glycogen synthesis, cell cycling and survival14. AKT 
is a key regulator of cell survival and is implicated in anti-apoptotic responses. 
Activation of AKT occurs by dual phosphorylation at Thr308 and Ser473, which is 
performed by PDK1 in response to PI3K signalling via PIP314. PI3K signalling is 
triggered in response to growth factors and cytokines, to G-protein coupled receptor 
(GPCR) activation and integrin signalling15. Aberrant signalling through this pathway 
has the potential to contribute to oncogenesis, and thus PTEN can be defined as a 











Furthermore, individuals with germline PTEN-inactivating mutations present with 
tumour-susceptible phenotypes such as Cowden syndrome, Bannayan-Riley-
Ruvalcaba syndrome and Proteus syndrome, which form a family of diseases known 
as PTEN hamartoma tumour syndromes. Clinically, PTEN hamartoma tumour 
syndromes are characterised by the elevated risk of forming benign or malignant 
tumours, especially in breast, endometrial and thyroid tissues16 17. This indicates a 
definitive role for PTEN as a tumour suppressor.  
PTEN can localise to either the nucleus or the cytoplasm and has different roles 
depending on its localisation. For PTEN to perform the role of lipid phosphatase of 
PIP3, it must transiently interact with the plasma membrane. Nuclear PTEN 
regulates cell proliferation, transcription and genomic maintenance18, and may even 
play a role in preventing double-stranded DNA breaks by inducing homologous 
recombination repair19. Cytoplasmic PTEN regulates inositol-3,4,5-trisphosphate 
receptors, which include those involved in calcium-mediated apoptosis and the 
transcriptional activation of the NF-κB pathway18.  
Figure 1. The function of PTEN with reference to the AKT pathway. Open connecting lines indicate 
inhibition or negative regulation, and arrows indicate activation or positive regulation. The inhibition of Bad 
and the FoxO transcription factors lead to the inhibition of apoptosis, as well as the activation of NF-κB 
transcription activity via IκB kinase (IKK). Inhibition of p53 via the activation of mouse double minute two 
homologue (MDM2) also suppresses apoptosis. Activation of cyclin D1 through glycogen synthase kinase 
3 (GSK3) and the activation of mammalian target of rapamycin complex 1 (mTORC1) are involved in 






Moreover, PTEN is reported to have protein phosphatase activity in addition to its 
lipid phosphatase activity. Targets of PTEN protein phosphatase activity include 
focal adhesion kinase, cAMP-response binding element 1 (CREB1)18 and cyclin D20.  
In addition, PTEN is also indicated in the stabilisation and transcriptional activity of 
p53, by direct association20 and through its phosphatase activity. It has been noted 
that although PTEN and p53 are tumour suppressors that are both frequently 
mutated in cancers, mutations in both genes very rarely occur concomitantly21. 
Furthermore, in cells with low or null PTEN expression, cellular concentrations of 
p53 are also significantly decreased22. This may indicate that loss of PTEN might be 
sufficient to remove the selective pressure to reduce p53 expression during cancer 
progression. PTEN stabilises p53 in a phosphatase-dependent manner by 
negatively regulating the phosphorylation of the ubiquitin ligase MDM2 by AKT. By 
preventing MDM2 phosphorylation, the ubiquitination and subsequent degradation 
of p53 is also prevented23. Expression of a lipid-phosphatase inactive variant of 
PTEN also increases levels of p53, indicating that there is a phosphatase and 
MDM2 independent mechanism by which PTEN regulates p53, although this 
mechanism is yet to be elucidated24. It has also been found that PTEN and p53 are 
able to form a complex within the nucleus, further developing the PTEN-p53 
network25. 
 
2.3. PTEN structure 
The structure of PTEN consists of 2 major structural-functional elements, the N-
terminal unit and the C-terminal unit. Within the N-terminal catalytic unit lies a PIP2 
binding domain, and a protein tyrosine phosphatase motif. The C-terminal unit 








The protein tyrosine phosphatase motif (PTP), localised in the N-terminal unit, is 
similar to those in other dual-specificity phosphatases, but with a slightly wider 
active site to accommodate the larger substrate of PIP327. The C2 domain of PTEN 
has been indicated to bind to the cell membrane and may also contribute to the 
correct positioning of the phosphatase active site at the membrane26. The 
C2/phosphatase domain interface is frequently mutated in cancer, with the residues 
mutated largely being involved in hydrogen bonding26. The instances of these 
localised mutations indicate that the interdomain hydrogen bonding is key for PTEN 
function. The PDZ domain plays a role in membrane localisation of PTEN, by 
interacting with the Pleckstrin homology (PH) domain in proteins such as MAGI228. 
However, the significance of the PDZ domain in membrane localisation has been 
called into question in studies by Hanafusa and colleagues. This group postulated 
that the phosphatase domain and C2 domain have a more prevalent role in the 
membrane affinity of PTEN, as removing either of these domains reduced the 
membrane affinity of PTEN29, whereas removing the PDZ domain did not 
significantly impact the activity of PTEN30. 
 
2.4. PTEN regulation 
The functions of PTEN are multifaceted, and no less can be said of its regulation. 
Regulation of PTEN occurs at the transcriptional, translational and post-translational 
level, all of which contribute to a highly controlled, finely tuned system. Positive 
regulators of PTEN at the transcriptional level include early growth response protein 
The N-terminal unit, 
containing the PIP2 








and PDZ domain. 
Figure 2. The crystal structure of PTEN, PDB access number 1D5R. The N-terminal domain is shown 
in blue, and the C-terminal domain in red. The structure shown above has deletions in the N-terminal 
region (amino acids 1-7) and in a loop region (residues 286–309) but has equivalent activity and affinity to 






1 (EGR1), peroxisome proliferator activated receptor γ (PPARγ), and p53, all of 
which have the capacity to bind directly to the PTEN promoter region31. There are 
also negative regulators of PTEN transcription, and these include the 
Ras/Raf/MEK/ERK pathway through c-Jun and NF-κB through the sequestration of 
the transcriptional activator CBP/p300. In some cancer models, further transcription 
factors appear to be involved in down-regulating PTEN during tumour formation and 
progression, for example mitogen-activated protein kinase kinase 4 (MKK4)32, 
transforming growth factor β (TGFβ)33 and the polycomb group protein BMI134 have 
been identified.  
 
Table 1. Transcriptional regulation of PTEN. 
Regulator Positive/Negative Mechanism of action Reference 
P5335 Positive 





Direct binding to PTEN 
promoter 
Edwin et al. 
(2006) 
PPAR37 Positive 
Direct binding to PTEN 
promoter 
Patel et al. 
(2001) 
EGR138 Positive 
Direct binding to PTEN 
promoter 
Virolle et al. 
(2001) 
NOTCH- RBPJ39 Positive 




NOTCH- HES140 Negative 
Direct binding to PTEN 
promoter 
Mumm et al. 
(2000) 
MKK432 Negative 
Through up-regulation of NF-κB 
signalling 
Xia et al. 
(2007) 
TGFβ33 Negative Through NF-κB signalling 







(SPRY- protein sprout homolog; PPAR- peroxisome proliferator-activated receptor; EGR1- 
early growth factor 1; RBPJ- recombing suppressor of hairless; HES1- hairy and enhancer of 
split 1; MKK4- mitogen kinase kinase 4; TGFβ- transforming growth factor beta; NF-κB- 
Nuclear factor kappa light chain enhancer of activated B-cells; CBP/p300- cyclic adenosine 
monophosphate response element binding element binding protein; BMI1- HDAC- histone 
deacetylase) 
 
NOTCH, a membrane-associated transcription factor40, is able to both positively and 
negatively regulate PTEN transcription. If NOTCH recruits and activates hairy and 
enhancer of split 1 (HES1), PTEN expression is downregulated, whereas if NOTCH 
inhibits the recombining suppressor of hairless (RBPJ), PTEN expression is 
upregulated40.  
The promoter region for the PTEN gene may also be susceptible to epigenetic 
modifications leading to the silencing of PTEN gene expression. This is believed to 
be caused by the hypermethylation of the CpG islands present in the PTEN 
promoter region. This mechanism of PTEN gene silencing has been tentatively 
identified in instances of gastric, colon and breast cancer31. 
NF-κB41 Negative 
Sequestration of CBP/p300 
complex 
Vasudevan 
et al. (2004) 
RAS/Raf/MEK/Erk42 Negative 




BMI 143 Negative 
Direct binding to PTEN 
promoter 





Epigenetic modification of the 
promoter identified in cases of 
breast44, endometrial45 and 
colorectal46 cancers. 









Epigenetic modification by 
HDAC 







Numerous microRNAs (miRNAs) have been implicated in the post-transcriptional 
negative regulation of PTEN. miRNAs are negative regulators of mRNA translation 
which function by binding to the 3’ untranslated region of the target mRNA, which 
either leads to prevention of translation or degradation of the target47. MiRNAs such 
as miR-130 and miR-21 are indicated to serve as tissue-specific regulators of PTEN 
synthesis31. MiR-21 negatively regulates PTEN by binding to the mRNA and 
preventing translation48. However, miR-130 is indicated to inhibit cell growth and 
increases apoptosis via direct interaction with PTEN in non-small cell lung cancer 
tissues, suggesting it plays a role as a positive regulator of PTEN activity49. MiR-130 
is an example of a hairpin miRNA involved in PTEN regulation, and polycistronic 
miRNAs such as miR367-302b may also be involved.  
 
 
Other post-translational modifications to the PTEN protein include phosphorylation, 
SUMOlyation, acetylation and oxidation (See figure 3). Phosphorylation of the C-
terminal region of PTEN is mediated by casein kinase 2 (CK2) and retains PTEN in 
Figure 3. An illustration of the domains of PTEN and how they are post-translationally modified. The 
enzymes responsible for the PTMs are shown at the top of the diagram, with the residues they target 
shown beneath the domain. Shown in blue are the sites of ubiquitination, in black the sites of oxidation, in 






a lipid-phosphatase inactive form in the cytoplasm50. Dephosphorylation of PTEN at 
the C-terminal region enables translocation to the plasma membrane and activation, 
but also destabilises PTEN and makes it more prone to ubiquitination by NEDD450. 
It is possible that the dephosphorylation of the PTEN C-terminal region is regulated 
by PTEN itself, through its protein phosphatase activity51, and that the ubiquitination 
of dephosphorylated PTEN by NEDD4 acts as a feedback regulation mechanism50.  
PTEN can also be oxidised by H2O2 produced as a result of epidermal growth factor 
or platelet-derived growth factor stimulation in cells with high levels of NADPH 
oxidase 1. Oxidation at cysteine 124 causes reversible, transient inactivation of 
PTEN52.  
 
2.4. Interactions between PTEN and viruses 
2.4.1. Epstein-Barr Virus 
PTEN is targeted by numerous different viruses during their replication. For 
example, during Epstein-Barr virus (EBV) infection, an EBV latent membrane protein 
has been found to cause hypermethylation of the PTEN gene promoter region via 
activation of DNA methyltransferase 1, leading to a decrease in PTEN protein 
production53.  EBV is an enveloped, double stranded DNA virus which has been 
associated with several human cancers, including nasopharyngeal carcinoma, 
Hodgkins lymphoma and gastric carcinoma. By non-random, global 
hypermethylation of the promoter regions of cancer-associated genes including 
PTEN, EBV infection increases the likelihood of oncogenesis in human cells53. 
 
2.4.2. Hepatitis C Virus 
PTEN has also been identified as a key host protein affected during Hepatitis C 
virus (HCV) infection. HCV is a small, enveloped, positive stranded RNA virus, 
strongly implicated in the development of hepatocellular carcinoma54. 
Immunofluorescence and Western blotting experiments have indicated that following 
HCV infection, the intracellular localisation of PTEN changes, in that there is a 
significant loss of PTEN from within the nucleus55. The loss of nuclear PTEN is 






and the formation of double-stranded DNA breaks, which in turn may be implicated 
in the oncogenic transformation of hepatocytes which can be associated with HCV 
infection. The loss of nuclear PTEN has been proposed to be caused by down-
regulation of Transportin-2- a regulator of nucleocytoplasmic transport- by HCV viral 
non-coding RNA II.55  
Furthermore, PTEN interacts with the HCV core protein to inhibit HCV replication. 
Overexpression of PTEN significantly reduced the levels of HCV RNA- by 
preventing post-binding step(s) in viral entry, possibly mediated by interaction 
between the lipid phosphatase domain of PTEN and the HCV core protein56. 
 
2.4.3. Avian Reovirus 
Avian reovirus (ARV) is a non-enveloped virus with a segmented, double-stranded 
RNA genome. For the virus to replicate, it subverts the host cell autophagy process. 
Autophagy is a key process in cellular homeostasis and plays a key role in the 
stress-induced survival response, to maximise nutrient availability57. 
Autophagosomes may provide membranous support for viral transcription and 
replication, and thereby support ARV growth. P17 is an ARV non-structural protein 
which acts as a CRM1-independent nucleocytoplasmic shuttling protein and induces 
autophagy during infection, as well as contributing to regulation of the host cell cycle 
and translation, by interfering with host signalling pathways58. P17 stimulates the 
PTEN, AMPK and PKR/eIF2α pathways, leading to downregulation of Akt and 
mTORC1 activity, which triggers autophagy58. In addition, p17 mediates the 
suppression of Tpr, a component of the nuclear pore complex, leading to an 
accumulation of nuclear p53, which in turn upregulates transcription of PTEN58. 
Consequently, the PI3K/Akt/mTORC1 signalling pathway is downregulated, leading 
to a cellular translation shut-off alongside upregulation of autophagy, which benefits 
viral replication.  
In conclusion, while interaction of viral proteins with PTEN have been demonstrated 
for several human viruses, there are many other viruses associated with human 
cancers (such as papillomaviruses and polyomaviruses) and other viruses that have 
the ability to transform human cells but for which no data on the interaction of these 








Adenoviruses are double stranded, non-enveloped DNA viruses, with a genome of 
around 36kb. Four genera of adenoviruses exist, and they are so categorised based 
upon bioinformatic analysis. Human adenoviruses are from the Mastadenovirus 
genus and are divided into 7 species, named A through G, with at least 57 types 
existing between these species. Within human cells, adenoviruses exhibit some 
degree of cell tropism, where the differences between types may be attributed to 
differences in the fibre knob protein.59 
 
2.5.1. Structure 
The adenovirus capsid is constructed from 3 major proteins- penton, hexon and fibre 
proteins; and several other smaller proteins, known as cement proteins60. The 
capsid is an icosahedron of over 900Å in diameter, composed of 240 trimeric hexon 
proteins, with penton base and fibre proteins present at each of the 12 vertices of 
the icosahedron61. The penton base serves as the attachment site for cell surface 
integrins αvβ3 and αvβ5 during viral entry, which mediates viral internalisation. 
Furthermore, the penton base provides a site for the fibre shaft to penetrate and 








The lifecycle of the adenoviruses can be divided into early phase and late phase 
events, with the early phase events occurring before viral DNA replication, and the 
late phase events occurring after.  
Entry of adenoviruses into human cells is largely dependent on interaction of the 
fibre protein knob domain with the Coxsackie Adenovirus Receptor (CAR), although 
some types possess affinity for the CD46 receptor or desmoglein 2 instead, 
principally types from Species B61. Sialic acid and heparan sulphate-containing 
proteoglycans also facilitate virus entry, for some members of species D and G and 
B and C, respectively62.  
Adenoviruses also bind to soluble factors, including lactoferrin63 and factor X62. 
CAR forms part of epithelial tight junctions and is present on most human cells. 
Three molecules of CAR bind to three molecules of the adenovirus fibre protein to 
induce endocytosis of the virion.  To support virus internalisation, the penton base 
protein binds to integrins αvβ3 and αvβ5, via a conserved RGD motif, which causes 
integrin clustering and associated integrin transmembrane signalling via PI3K, 
Figure 4. A diagrammatic representation of the structure of human adenoviruses, from 
‘Adenoviruses: update on structure and function’. A schematic to illustrate the major components of 
the adenovirus particle. Highlighted are the 3 major capsid proteins- fibre, hexon and penton base- the 
minor “cement” proteins IIIa, VI, VIII, IX, and the smaller core proteins- V, VII, Mu, terminal protein, IVa2 
and protease. The proteins are not to scale, although approximate shapes are given based on X-ray 






p130CAS and Rho GTPases64. These signalling events lead to the polymerisation of 
actin molecules localised to the site of penton binding, enabling endocytosis of the 
virion. In addition, the penton-integrin interactions initiate the uncoating of the virion 
at the cell surface through the loss of fibre proteins and exposure of cement protein 
VI, which prepares the virion for cell entry65. 
After the fibre-less virus particle has been endocytosed, it must then escape the 
endosome. For endosomal escape, cement protein VI penetrates the endosomal 
membrane, causing membrane disruption and allowing the virus particles to be 
released64. The acidification of the endosome during maturation may also have 
significance in the release of viral capsid proteins and also in the activation of the 
viral associated viral protease, which is required for the final disassembly of the 
virion at the nuclear pore59.  
After the virions have exited the endosome, they are transported to the nucleus 
along with microtubules, which is dictated by hexon binding. Hexon trimers are also 
responsible for the association of the viral components to the nuclear pore complex. 
Binding of the Ad virion to the nuclear pore complex triggers the complete uncoating 
of the virion and the transport of viral DNA into the nucleus59. Viral DNA enters the 
nucleus in complex with core protein VII at around 2 hours post infection. 
The viral E1A gene is an immediate early gene that is transcribed without 
requirement for any other viral protein. It encodes two major phosphoproteins of 289 
and 243 amino acids responsible for the regulation of viral and cellular protein 
expression at the transcriptional level66, and the induction of the host cell cycle to 
enter S-phase67, by interfering with proteins in the retinoblastoma (Rb) pathway6.  
Following entry into the nucleus, and transcription of early viral genes by host cell 
RNA polymerase II, the virus genome is replicated by the E2 gene products (E2-
72K, E2B-DNA polymerase and terminal protein), assisted by host cell proteins68.  
Viral protein E1B-19K blocks apoptosis by inhibiting the downstream effectors of 
TRAIL and TNFα, which are pro-apoptotic signalling pathways to which the cell is 
sensitised to by the dysregulation of the cell cycle by E1A69. For example, it can bind 
to pro-apoptotic proteins Bak and Bax to prevent the opening of the mitochondrial 
permeability transition pore, and hence mitochondrial-dependent apoptosis70. E1B-







The E2 gene encodes the viral DNA polymerase, preterminal protein and the DNA-
binding protein, all of which are essential for viral DNA replication71. 
E3 proteins are involved in the modulation of the host immune response in that they 
are involved in protecting the adenovirus infected cells from MHC-restricted 
cytotoxic T-cells and in preventing immune mediated inflammation. The E3 gene 
also encodes for the adenovirus death protein (ADP), which is involved in the 
efficient release of progeny virions72. 
The viral E4 gene is responsible for producing at least six viral polypeptides by 
alternative RNA splicing. The most important of these in the viral lifecycle are E4orf3 
and E4orf6. Both proteins interact independently of the other indirectly to facilitate 
viral DNA replication, synthesis of late viral proteins and inhibition of host-cell protein 
synthesis73. E4orf3 is involved in SUMOlyating host proteins involved in DNA 
damage repair, to ensure high fidelity viral DNA synthesis73. It has also been 
proposed to regulate the structure and hence replication of the viral genome, by 
inhibiting the host cellular response to double-stranded DNA breaks74. E4orf6 is 
involved in the prevention of apoptosis by degrading p53- in association with 
E1B55K7.  
The L1-L5 gene products are involved in the structure and assembly of the capsid of 
the virus69. 
 
2.5.2. Adenoviruses as oncolytic therapeutics 
Oncolytic viruses are able to selectively enter and replicate within cancer cells, while 
being unable to do so in normal cells. These viruses can be naturally occurring or 
genetically engineered for cancer cell specificity75.  Oncolytic viruses aid the 
stimulation of the immunogenic response against the tumour cells by inducing active 
lysis of the cancer cells, or by delivering a transgene which initiates apoptosis or 
necrosis76.  
Adenoviruses present several advantages as a therapeutic- they are easy to 
genetically or chemically manipulate, they are able to be produced at high titres, and 
can transduce dividing and non-dividing cells. Furthermore, adenovirus DNA is not 
integrated into the host genome during infection, which reduces the risk of 






therapy is the natural tropism of adenoviruses towards the liver, which may induce 
hepatocytotoxicity. This is mediated by the binding of hexon protein to Factor X, 
which enables the binding of Ad5 to the heparan sulphate proteoglycan receptors 
present on hepatocytes78. In addition, adenovirus infection induces a host immune 
response, either by the innate or adaptive immune systems if the patient has had 
previous exposure to the virus79. 
To prevent hepatotoxicity and the immunogenic response to wild-type adenoviruses, 
numerous methods of modification have been developed. Chemical modification by 
complexing the adenovirus with a synthetic polymer can be performed by chemical 
conjugation or by manipulating the anionic surface of the virus to encourage 
electrostatic interaction with an anionic polymer. By coating the virus surface in a 
polymer, it is possible to shield it from the host immune response. One of the 
benefits of using synthetic polymers to aid viral entry is the level of optimisation 
which can be performed, to maximise uptake efficiency and specificity, whilst 
maintaining the cancer cell-killing properties of the adenovirus.  
In addition, affinity ligands can be attached to the polymer coat to encourage active 
targeting of cancer cells. Affinity ligands could be an antibody, a peptide, an aptamer 
or a polysaccharide with high affinity to a plasma membrane receptor which is over-
expressed in cancer cells and under expressed in normal cells. For example, cRGD 
is a peptide with high affinity for αvβ3 and αvβ5 integrins, which are frequently 
expressed on growing tumour cells. Use of affinity ligands increases the selectivity 
and efficiency of viral accumulation at tumour cells76.  
A major drawback of chemically altering adenoviruses for oncolytic virotherapy is 
that the modifications cannot be replicated in the progeny virions. The progeny 
virions may then go on to cause unwanted, non-specific interactions with normal 
host tissues. Conditionally replicating adenoviruses have genetically modified 
genomes which ensure that cancer cell targeting modifications are passed onto the 
next viral generation77.  
One method of designing conditionally replicating viruses is to delete viral genes 
which are essential for viral replication during infection of normal cells but are 
complemented in cells displaying some of the hallmarks of cancer, such as aberrant 






For example, Onyx-015 is a genetically modified adenovirus with a deletion in the 
E1B55K gene, corresponding to the p53 binding domain77. In infection of normal 
cells, E1B55K interacts with p53, in conjunction with viral protein E4orf6, to prevent 
apoptosis triggered by viral E1A gene products. In approximately 50% of human 
cancers p53 is deleted or mutated80, and Onyx-015 is able to successfully replicate 
in these p53-null cells but replicates poorly in normal cells with wild-type p53, as the 
lack of p53 binding causes the cell to undergo cell cycle arrest81. However, as 
E1B55K plays additional roles during the viral lifecycle, Onyx-015 replication in 
cancer cells is less efficient in replication than wild-type adenovirus as the mutant 
E1B55K prevents effective nuclear export of viral mRNA79.  
A modified virus that is similar to Onyx-015, named H101, has been approved for 
use in China for treatment of head, neck and oesophageal cancer82. It has deletions 
in both the E1B and E3 genes, leading it to replicate selectively in p53 null cells. The 
deletion to the E3 gene removes the coding region of the adenovirus death protein, 
which may improve the safety of the virus83. 
Other attempts to design a selectively replicating adenovirus involve making small, 
specific mutations to key genes, such as the E1A gene. Such small mutations are 
designed to interfere with one function of the viral protein, to retain viral potency 
whilst enabling selective replication84. E1A permits viral replication by interacting 
with cellular protein Rb to induce entry into the S-phase of the host cell cycle. Where 
the Rb-binding domain of the E1A gene is mutated, the virus is able to replicate in 
cancer cells with an already dysregulated cell cycle caused by, for example, 
mutation to Rb family genes85. 
Furthermore, tumour selectivity can also be conferred by placing the adenoviral 
early proteins under the control of a promoter which is upregulated in cancer cells. 
For example, placing the E1A gene under the transcriptional control of the human 
telomerase reverse transcriptase (hTERT) promoter enables specific replication in 
cancer cells, as hTERT is over expressed in cancer cells to prolong the lifespan of 
the cell86. 
2.5.3. Interactions between PTEN and Adenoviruses 
Thus far, work by previous Blair group students has elucidated that there may be a 
paradoxical relationship between PTEN and adenoviruses during viral replication, in 






depleted by RNA interference. However, the cellular level of PTEN is markedly 
decreased during the early phase of Ad5 infection in cells that contain normal, 
unmutated PTEN. Infection with Ad5 has been shown to decrease the cellular 
concentration of PTEN by 50% at 24 hours post infection (Beth Mason and Lisa 
DeCotret, unpublished results). The expression of PTEN mRNA was also reduced 
by approximately 50% in Ad5 infected A549 cells, as shown by RT-QPCR analysis 
and was decreased in both untreated A549 cells and in cells in which PTEN mRNA 
had been depleted by RNA interference (Amy Turner, unpublished results). 
However, PTEN expression was partly restored following inhibition of proteasomes 
by MG132, which implies that there may also be post-translational degradation of 
PTEN protein during Ad infection. 
In investigating the contribution of p53 to PTEN regulation, it was found that the 
base level of PTEN was lower in p53 null cells, perhaps indicating that p53 partially 
contributes to the regulation of PTEN expression (Amy Turner, unpublished results). 
However, it was not determined whether p53 mediation of PTEN expression 
occurred in a cell specific manner.  
In addition, it has been well documented that adenovirus proteins regulate p53 
during infection, and therefore may also indirectly regulate PTEN. 
 
2.6. Aims of this project 
• Identify whether PTEN promoter activity changes during Ad5 infection 
• Identify whether p53 status of cells affects the activity of the PTEN promoter 
during Ad5 infection 
• Produce a PTEN-expressing U87MG cell line 
• Compare progression of Ad5 infection in a PTEN-expressing cell line with 











3. Materials and Methods 
3.1. Buffers 
Table 2: Buffers used throughout this project and their composition 
Buffer  Composition 
TBST 20mM Tris HCl, 137mM NaCl, 0.05% 
Tween 20; pH 7.4 
TBE 90mM Tris HCl, 90mM boric acid, 2mM 
Na2EDTA  
DNA loading buffer (New England 
Biolabs Cat No: B7025S) 
2.5% Ficoll®-400, 10 mM EDTA, 3.3 
mM Tris HCl, 0.02% Dye 1 (pink) 
0.001% Dye 2 (blue); pH 8 
RIPA 20mM Tris HCl, 150mM NaCl, 1mM 
Na2EDTA, 1mM EGTA, 1% NP-40, 1% 
sodium deoxycholate, sodium 
pyrophosphate 2.5 mM, 1 mM β-
glycerophosphate, 1 mM Na3 VO4, 1 
µg/ml leupeptin 
SDS running buffer 25mM Tris HCl, 192mM glycine, 3.5mM 
SDS; pH 8.3 
SDS loading buffer 63 mM Tris HCl, 10% glycerol, 2% 
SDS, 0.0025% bromophenol blue, pH 
6.8 
Towbin transfer buffer 25mM Tris HCl, 192mM glycine, 20% 
methanol; pH 8.3 
Passive lysis buffer As supplied by Promega 
PBS 137mM NaCl, 2.7mM KCl, sodium 






3.2. Cell Lines 
Table 3: Cell lines. Cell lines used throughout this project, their PTEN and p53 status and origin. 
Throughout this project, the following cell lines were used: 
Name PTEN status P53 status Origin Notes 

























Large intestine carcinoma  




Large intestine carcinoma  
Phoenix 
Ampho87 








Table 4: Antibodies. Antibodies used throughout this project, their species, application, working dilution, supplier and catalogue number (where 
relevant). 
Antibody Species Supplier Cat No Application Working 
Concentration 
Anti-PTEN Rabbit Cell Signalling Technology 9559 Western blot 1:1000 
Anti-PTEN Mouse Santa Cruz Sc-7974 Immunofluorescence 1:100 
Anti-GAPDH Mouse CalBiochem (Merk) CB1001-
500UG 
Western blot 1:10000 
Anti-fibre Rabbit Made in-house  Western blot, 
immunofluorescence 
1:2000 
Anti-penton Rabbit Made in-house  Western blot, 
immunofluorescence 
1:1000 
Anti-E1A Mouse Santa Cruz Sc-430 Western blot, 
immunofluorescence 
1:1000; 1:100 
Anti-72K Mouse Kindly provided by K.Leppard 
(University of Warwick) 
 Western blot 1:5000 
Anti-DBP Rabbit Kindly provided by K.Leppard 
(University of Warwick) 
 Immunofluorescence 1:10 
Anti-mouse Horseradish 
Peroxidase 
 Sigma 1002231745 Western blot 1:1000 
Anti-rabbit horseradish 
peroxidase 








Goat Invitrogen A21203 Immunofluorescence 1:1000 
Anti-rabbit AlexaFluor-
488  




3.4. Mammalian cell culture 
Cells were sub-cultured every two to three days, when approximately 80% 
confluent. Spent medium was removed, cells were washed with PBS, then 
trypsinised. DMEM with 10% FBS and 1% Pen/Strep was added and cells were 
dispersed by gentle aspiration. Approximately 2ml of cell suspension was retained in 
the flask, and the remainder discarded. Medium was added to the flask (around 
10ml for a T75). Cells were incubated at 37°C in a humidified atmosphere 
containing 5% CO2. For preparation of cells in six-well plates, the cells in solution 
following dispersion were counted using a haemocytometer and a seeding density of 
0.3 x 106 cells per well was used. For a 12-well plate the seeding density was 0.1 x 
106 cells per well, and for a 24 well plate the seeding density used was 0.05 x 106 
cells per well.  
3.5. Bacterial cell culture 
Bacterial cultures were grown in LB medium supplemented with 100μg/ml ampicillin. 
Colonies were picked form LB agar plates and inoculated into 10ml LB medium plus 
ampicillin, followed by overnight growth with shaking at 37°C. From the liquid starter 
culture, 1ml starter was added to 100ml LB with ampicillin and left to grow overnight 
at 37°C with shaking for use in midi-prep plasmid DNA isolation. 
3.6. Small and medium scale plasmid preparation 
Small scale plasmid preparation (mini-prep) was performed using the QuiaGen 
system, following manufacturers instructions. 
Medium scale plasmid purification (midi-prep) was performed using the QiaGen 
MidiPrep system, following manufacturers instructions. Cells from a 100ml overnight 
culture were harvested by centrifugation at 14000g and 4°C for 40 minutes. The cell 
pellet was resuspended in 4ml of buffer P1. Four millilitres of buffer P2 was added, 
followed by vigorous inversion. The mixture was incubated at room temperature for 
5 minutes before 4ml of prechilled buffer P3 was added and vigorously inverted 
again. The tube was incubated on ice for 15 minutes. After buffer P3 was added, a 
white precipitate appeared which contained genomic DNA, proteins and cell debris. 
After centrifugation, the supernatant was transferred to a clean Falcon tube and 
centrifuged for a further 15 minutes, as described above. The QiaGen tip was 
equilibrated using 4 ml of buffer QBT, which was emptied from the column by gravity 
flow before the supernatant from the previous step was applied to the resin. The 
column was washed with two washes of 10ml buffer QC. DNA was eluted from the 




room-temperature isopropanol was added to the eluate to precipitate the DNA. The 
tube was centrifuged at 14000g for 60 minutes at 4°C. The supernatant was 
carefully decanted and discarded. The DNA pellet was washed with 2ml 70% 
ethanol and centrifuged in the same conditions as before for 60 minutes. The 
supernatant was discarded, and the pellet resuspended in 100μL nuclease-free 
water. A nanodrop at 260nm was used to calculate the concentration of DNA. 
3.7. Agarose gel electrophoresis 
A 0.75% agarose gel was made by heating 0.75g of agarose and 100ml of TBE 
buffer in a microwave oven, until the agarose had completely dissolved. The gel 
mixture was left to cool slightly, until it reached 50°C, and 1μL SybrSafe Gel Stain 
(ThermoFisher) was added. The mixture was then gently cast into a stand with a 
comb already inserted. The gel was left to set completely before use. Before being 
loaded onto the gel, 0.5μg of each plasmid was combined with 2μL of Loading 
Buffer (New England Biolabs). The gel was placed into an electrophoresis tank, and 
TBE buffer was added to the tank until a layer of buffer covered the gel. The 
plasmids were then loaded alongside a 1kb DNA ladder (New England Biolabs), and 
a voltage of 100V was applied for 1 hour. A fluorescent image of the agarose gel 
was captured using a Fuji FLA5000 imager. 
3.8. E.coli transformation 
An aliquot of competent E.coli DH5α (kindly provided by Vikki Easton, University of 
Leeds) was thawed on ice, and 1μL of miniprep or 2μL of plasmid was added. The 
tube was gently agitated and incubated for 30 minutes on ice. The mixture was heat-
shocked at 42°C for 45 seconds and incubated on ice for two minutes. Eighty 
microlitres of SOC medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose, ThermoFisher)was added 
and incubated at 37°C for 30 minutes with shaking. Bacteria were spread on LB 
agar plus ampicillin plates, warmed to room temperature, left to adsorb for several 
minutes, inverted and incubated at 37°C overnight.  
3.9. Mammalian cell transfection 
Twenty-four hours prior to transfection, cells were seeded into antibiotic-free DMEM 
+ 10% FBS in the wells of a 6, 12 or 24-well plate to achieve 50-80% confluency at 
the time of transfection. On the day of transfection, two tubes were made up; Tube A 
contained 1μg of plasmid DNA in 224μL of OPTIMEM, tube B contained 4μL 
Lipofectamine 2000 and 21μL OPTIMEM. Tube B was prepared first and incubated 




and incubated at room temperature for a further 20 minutes. The cells to be 
transfected were washed twice with PBS. OPTIMEM (900μL) was added to the 
combined tube A plus B, and the contents added to cells. The plate was incubated 
at 37°C for 4 hours before an additional two millilitres of serum-free medium was 
added. Cells were harvested 24 or 48 hours post-transfection. 
3.10. Production of retroviruses and cell transduction 
Phoenix Ampho cells were seeded at 4.5x105 cells per well in a 6-well plate. At 24 
hours after seeding, cells were transfected with 2.5μg pBABE PTEN plasmid, and 
Lipofectamine 2000, at a ratio of DNA to lipofectamine of 1:2.5 as described above. 
Cells were incubated overnight with the transfection complex and medium was 
replaced with DMEM + 10% FBS + 1% P/S, supplemented with 20mM HEPES-KOH 
(pH 7.5). At 48 hours post transfection, the supernatant containing retroviruses was 
harvested, filtered through a 0.45μm filter and polybrene was added to a final 
concentration of  4μg/ml and gently pipetted to mix. The removed medium was 
replaced with the HEPES supplemented DMEM+FBS+P/S. At seventy-two hours 
post transfection (24 hours later), a second batch of retroviral supernatant was 
harvested, filtered and treated with polybrene as described above. Supernatants 
were used immediately to transduce U87MG as described below. 
Twenty-four hours prior to infection, U87MG cells were seeded at 4.5x105 cells per 
well of a 6-well plate. For transduction, the medium was removed and replaced with 
the retrovirus-containing supernatant that had been harvested at 48 hours post 
transfection. Cells were incubated for 4 hours at 37°C, with agitation every 15 
minutes. The retrovirus-containing supernatant was removed, cells were washed 
twice with PBS and fresh growth medium was added. At twenty-four hours after the 
initial transduction, a second round of transfection was performed using the second 
batch of harvested retrovirus-containing supernatant.  
Twenty-four hours after the second round of transduction, the growth medium was 
changed to medium containing 2μg/ml puromycin, to select for stably transduced 
cells. Selection was performed for 14 days, with medium changes every two days. 
Cells were expanded to T25 flasks and the concentration of puromycin was reduced 
to 1μg/ml. 
3.11. Limiting dilution 
Cells from a stable polyclonal population were counted using a haemocytometer and 
diluted into conditioned medium (derived from confluent U87MG cells, sterile filtered 




cells per ml. Medium used throughout isolation was supplemented with puromycin at 
2mg/ml. The corner well of a 96-well plate was seeded with 1000 cells to act as a 
focal plane, and all other wells were seeded with 100µL of the 5 cells/ml solution.  
The plates were incubated for 7 days before being checked for cell growth using an 
inverted microscope.  
Wells that contained single colonies were considered to be candidate monoclonal 
cell lines and expanded into wells of a 24-well plate once 80% confluency was 
reached. From the 24-well plate, growing cells were expanded into wells of a six well 
plate once 80% confluent. Before reaching confluency, cells from each well were 
expanded into a T25, then a T75 flask. 
3.12. Preparation of mammalian cell lysates 
Cells were washed with PBS, treated with trypsin for five minutes at 37°C, and 
complete medium was added. The cell suspension was centrifuged at 15,000 rpm 
for 5 minutes at room temperature to pellet cells. Cells were resuspended in PBS, 
centrifuged, and resuspended in RIPA buffer + protease inhibitors and left on ice for 
30 minutes. The samples were centrifuged at 15000 g for 5 minutes at 4°C. The 
supernatant was carefully removed and stored at -80°C until further use.  
3.13. Protein assay 
To determine the protein concentration of samples, a BCA assay was performed. 
Standard protein concentration samples of 0, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1 
mg/ml were prepared using BSA and added in duplicate into wells of a 96 well plate. 
Cell lysates, prepared in RIPA as described above, were diluted 1:10 before addition 
in duplicate, to the wells of the 96 well plate. BCA reagent (ThermoScientific) was 
added to each well and the plate incubated for 30 minutes at 37°C in the dark. 
Absorbances were recorded at 562nm using a plate reader and used to calculate 











3.14. SDS PAGE 
SDS-polyacrylamide gels for SDS-PAGE were cast in an Atto gel apparatus. For 
12% gels the resolving and stacking gels were prepared as follows: 
Table 5: SDS-PAGE gel composition. 
Component Resolving Gel Stacking Gel 
DH2O 3.95ml 4.83ml 
30% acrylamide 4.8ml 1ml 
1.5M Tris HCl pH 
8.8 
3ml  
0.5M Tris HCl pH 
6.8 
 2ml 
10% SDS 120µL 80µL 
10% APS 120µL 80µL 
TEMED 12µL 8µL 
 
The resolving gel was made first, mixed gently then poured into the gel plates. A 
layer of butanol was gently pipetted over the top of the gel and was left to 
polymerise 15-30 minutes. Once polymerised, the butanol was removed, and the 
stacking gel was made up and gently added on top of the resolving gel. The comb 
was inserted, and the gel left to polymerise for 30-45 minutes.  
Once the gel had set completely, the casting stand, spacer and comb were 
removed, and the gel was assembled in the running tank. The chamber was filled 
with 1x SDS Running buffer so that both the bottom of the gel and the wells were 
completely submerged, taking care to remove any air bubbles.  
The cell lysates were prepared by adding 4µL of SDS loading buffer to the volume 
of sample which contained 25-50µg protein (as measured by BCA assay) before 
heating at 95°C for 5 minutes.  Samples were loaded alongside 6µL protein 
molecular mass ladder (MagiMark XP). Electrophoresis was performed at 100V for 
20 minutes, until the samples had migrated through the stacking gel, then the 
voltage was increased to 150V for around 50 minutes to one hour, ensuring the 
bromophenol marker dye was close to the bottom of the gel.  
3.15. Western blotting 
Proteins were transferred from the gel to a PVDF membrane (Immobilion). The 
membrane was soaked in methanol for 5 minutes, then in Towbin transfer buffer for 




minutes. The gel was removed from the tank and the glass plates and was 
sandwiched between the two filter pads, with the PVDF membrane on the 
underside. The sandwich was rolled to remove air bubbles, assembled into a semi-
dry blotting apparatus and transferred at 15V for one hour using PowerPac 300 
(BioRad).  
The membrane was removed from the transfer apparatus and treated with blocking 
buffer (0.5g milk powder in 0.1% TBS-Tween 20 (TBST)) for one hour at room 
temperature with gentle rocking. The blocking buffer was removed, and the primary 
antibody at an appropriate dilution (see Table 4) in blocking buffer was added and 
rocked overnight at 4°C. The membrane was washed six times with 0.2% TBST for 
5 minutes each time, before the secondary antibody (diluted 1:1000 in blocking 
buffer) was added and rocked for one hour at room temperature. The membrane 
was washed as before and imaged using Amersham ECL Select Western Blotting 
Detection Reagents (400μl of both A and B) that were pipetted onto the membrane 
which was sandwiched between two acetate sheets. Images were captured using a 
Fuji LAS-3000 after 30 seconds, one-minute or two-minute exposure times, applying 
fresh ECL reagents for each exposure. When analysing two different proteins, the 
membrane was blocked as before after imaging, followed by repeating the antibody 
treatment and washing steps as above.  
3.16. Infection with Adenovirus 
Cells were cultured on the appropriate plate until 80-90% confluent. Medium was 
removed and replaced with 0.5ml serum-free medium. Cells were infected with Ad5 
(kindly provided by Ms Binta Bettaye, University of Leeds) at 300 virus particles per 
cell (vp/cell) for wtAd5 and 600vp/cell for Ad5EGFP. Cells were incubated at 37°C 
for one hour with regular agitation, a further 2ml of serum-free medium was added 
and incubated at 37°C in a humidified atmosphere containing 5% CO2 for either one 
or two days. 
3.17. Luciferase assay 
For transfection of luciferase-gene-containing plasmids, all plasmids were diluted to 
around 20ng/μL. Transfection was performed as described as above with Tube B 
containing 4μL of Lipofectamine 2000 and 21μL of OPTIMEM per well to be 
transfected, and after addition of the two components, tubes were incubated at room 
temperature for 5 minutes. Tube A was prepared using 1μL of plasmid DNA (at 
20ng/μL), 19μL of Renilla luciferase plasmid DNA (also at 20ng/μL), and 224μl 




temperature for 20 minutes. Meanwhile, cells were washed twice with PBS. After 
Tubes A and B combined had been incubated, 900μl of OPTIMEM was added to 
each tube and the contents were added to the washed cells. Cells were incubated at 
37°C for 4 hours, an additional two millilitres of serum-free medium was added and 
incubated for a further two days.  
To measure luciferase activity, the Promega Dual Luciferase Assay system was 
used. In brief, the medium was removed from the cells, the monolayer washed with 
PBS and cells were lysed with Passive Lysis Buffer (PLB) for 15 minutes at room 
temperature, with rocking. Each cell sample was assayed at various dilutions- 
between no dilution and 1:500 dilution in PLB. Twenty microlitres of each dilution 
was dispensed in triplicate into wells of a white 96 well plate. A FLUOstar OPTIMA 
luminometer (BMG Labtech) was used to dispense 50μL each of LAR II and Stop & 
Glo reagents per well and to measure the resulting luciferase activity. 
3.18. Statistical Analysis 
For each measured sample, the mean firefly:renilla activity was calculated using 12 
values recorded for each luciferase activity. For each biological repeat (composed of 
a set of triplicate measurements), the average mean firefly:renilla of the three 
triplicates was calculated, then normalised to the corresponding pGL3-basic sample 
or to the mock-infected value. 
A two-tailed, unpaired student’s t-test was used to assess the significance of any 
difference within the data sets, with a p-value of less than 0.05 determining 
differences between experimental data as statistically significant.   
 
3.19. Immunofluorescent antibody staining 
Cells were grown in the appropriate plates until approximately 70% confluent, 
medium was removed and cells were washed twice with cold PBS. Cells were fixed 
using ice-cold 100% methanol for 10 minutes, washed three times with PBS and 
blocked with 10% normal goat serum (NGS) for 20 minutes at room temperature. 
Cells were washed with PBS three times and incubated with 200μL of the 
appropriate antibody diluted in PBS plus 1% NGS and 0.1% Triton X-100 for one 
hour at room temperature, with rocking. The cells were washed three times with 
rocking, for 10 minutes each time, with PBS, before being incubated with 200μL 
Alexa Fluor-488-conjugated anti-mouse or rabbit immunoglobulin (diluted in PBS 
plus 1% NGS +0.1% Triton X-100) for 30 minutes at room temperature, in the dark, 




rocking. DAPI (200μL of a 1μg/ml stock solution) was added to the cells and 
incubated at room temperature, in the dark, with rocking, for 15 minutes. Cells were 
washed three times with PBS before being stored in PBS at 4°C in the dark. Images 
were obtained using an EVOS FL Auto Fluorescence Imaging System microscope 
(Life Technologies).  
3.20. Flow Cytometry of infected cells 
Cells were seeded at 0.3x106 cells per well of a six well plate. Twenty-four hours 
post-seeding, cells were infected with Ad5EGFP at approximately 600 vp/cell, as 
described above. Cells were transduced at 37°C for 24 hours. After infection, 
medium was removed from cells, cells were washed gently with PBS and trypsinised 
at 37°C for 5 minutes. Cells were resuspended in serum-free medium and 
transferred to an Eppendorf tube. The cell suspension was centrifuged for 5 minutes 
at 180 x g. The supernatant was removed, and the cell pellet was resuspended in 
PBS. The cell suspension was recentrifuged as before, and the supernatant 
removed. To fix the cells, the cell pellet was resuspended in 4% PFA and incubated 
at room temperature for 10 minutes. The cells were centrifuged again, and the 
supernatant was removed. The cell pellet was then resuspended in 500μL of PBS. 
Samples were then analysed using flow cytometry. 
Flow cytometry was performed on a Cytoflex S cytometer, using the 488-525 laser. 
A total of 10,000 cells were measured for fluorescence in each sample. Gates were 
set using mock-infected A549 cells as the negative control, whereby fluorescence 
detected above the background fluorescence exhibited by mock-infected A549 cells 













4. Effect of Ad5 infection on the activity of the PTEN promoter region 
Previous research by the Blair group identified a 50% decrease in steady-state 
levels of PTEN protein and mRNA following Ad5 infection. This decrease could be 
attributed to viral effects at the level of transcription of the PTEN gene, for example 
by reduced activity of the PTEN promoter, reduced pre-mRNA splicing or other post-
transcriptional modification, or by reduced transport of PTEN mRNA from the 
nucleus to the cytoplasm. The PTEN promoter region has previously been identified 
and characterised, and contains a p53 binding region35, which may be relevant as 
p53 is targeted for proteasomal degradation during Ad5 infection by the Ad5 
proteins E1B55K and E4orf67.  
To identify whether Ad5 infection results in any change to the activity of the PTEN 
promoter, PTEN promoter-luciferase plasmids were transfected into several human 
cell lines known to support Ad5 replication and luciferase assays were performed as 
a measure of promoter activity. 
Luciferase reporter assays can be used to monitor the activity of a genetic response 
element of interest (such as a promoter/enhancer region) by placing a luciferase 
gene under its control. During the assay, the luciferase enzyme in cell-free extracts 
of transfected cells reacts with its substrate, luciferin, to produce bioluminescence. 
The luciferase genes from firefly (Photinus pyralis) and sea pansy (Renilla 
reniformis) are commonly used for this purpose as their properties and the luciferase 
enzymes produced have been well-characterised. 
In dual luciferase assays, a plasmid containing the gene for Renilla luciferase under 
the control of a constitutively-active promoter (such as the cytomegalovirus, CMV, 
immediate early promoter) is co-transfected with a plasmid containing the 
promoter/enhancer element of interest driving firefly luciferase. Renilla luciferase 
acts as an internal control that monitors transfection activity, as its expression is 
independent of cell-type specific transcription factors. Renilla luciferase activity can 
therefore be used to “normalise” firefly luciferase activity by correcting for any 
variation due to transfection efficiency between samples. The Promega Dual 
Luciferase system first generates a luminescent signal from the firefly luciferase, 
using LAR II reagent; and subsequent addition of the “Stop and Glo” reagent both 
quenches this luminescence and activates the bioluminescence of the Renilla 
luciferase.  
In these experiments, PTEN promoter regions were used extending from either -




+1) or –2526 to -427 base pairs upstream of the transcription start site linked to 
firefly luciferase. These plasmids were kindly provided by Dr V. Stambolic (Amgen 
Research Institute and Ontario Cancer Institute, Toronto). If the PTEN promoter 
region is active, the firefly luciferase gene will be transcribed and translated, 
resulting in bioluminescence when the Stop and Glo reagent is added. The use of 
Renilla luciferase as a control permits comparison of transfections in different cell 
lines by providing a normalisation control. 
Luciferase assays were performed in triplicate and the mean luciferase activity was 
calculated for each sample. 
4.1. Initial characterisation of PTEN promoter-luciferase plasmids 
The two plasmids received from V.Stambolic (Amgen Research Institute and Ontario 
Cancer Institute) were named PTEN full (region -2526 to -427) and PTEN short 
(region -1359 to -427).  
Initially, the plasmids were sent for sequencing to ensure the promoter regions were 
accurate. A BLAST search on the sequencing results revealed a 97.06% identity of 
PTEN full to the PTEN RefSeqGene on chromosome 10. PTEN short showed a 
99.36% identity to the same reference sequence. 









Figure 5: Analysis of PTEN promoter plasmids by agarose gel electrophoresis. 
Aliquots (containing 0.5μg DNA) were separated by electrophoresis on a 0.75% 
agarose gel at 100V for an hour, and the image obtained using an FLA5000 imager. 
SybrGreen was used to visualise DNA within the gel. Each plasmid separates into 
two bands on the agarose gel- the top band is likely to be linear plasmid, as it 
migrates more slowly through the gel, and the bottom band likely to be supercoiled 
plasmid, which migrates quickly through the gel88.  
 
Dual luciferase assays were performed following transfection of each plasmid (along 
with the control Renilla plasmid) in two different cell lines to identify which promoter 






Figure 6: Initial characterisation of the activity of PTEN promoter regions. Dual 
luciferase assays were performed using lysates of cells transfected by each PTEN 
promoter plasmid. Mean firefly:renilla values were normalised to the luciferase 
activity of pGL3-basic, the negative control, in (A) 293T cells and (B) A549 cells.  
As the mean firefly:renilla activity of the full PTEN promoter was significantly greater 
than that of the shorter variant in both cell lines, it was used in subsequent 
transfections. As A549 cells support Ad5 infection and also represent an epithelial 
cell type targeted during Ad5 infection in humans, most experiments were performed 
using this cell line. 
 
4.2. The activity of the PTEN promoter in Ad5-infected A549 cells 
A549 cells were transfected with the PTEN full-luciferase plasmid and Renilla 
luciferase, using Lipofectamine 2000 for transfection. At 24 hours post-transfection, 
samples were either mock infected or infected with Ad5 at 300vp/cell. 24 hours post-
infection, cells were harvested using Passive Lysis Buffer (Promega) and diluted 
appropriately. The luciferase activity of each sample was measured in triplicate, the 
firefly:renilla activity for each repeat calculated, and an average taken. The mean 
firefly:renilla activity for each condition was then normalised to the mean 
firefly:renilla luciferase activity calculated for pGL3-basic, the negative control. Raw 
luciferase and normalised data are shown in Appendix. Results were expressed as 
fold change in luciferase activity with respect to mock-infected A549 cells which was 
set as 1. In Fig.7, 10 biological repeats of this transfection were performed. A 
student’s t-test (n=10) was performed to identify whether any change to the PTEN 
promoter activity post-infection was significant. The p-value calculated was 0.922. 
Using p≥ 0.05 to identify a null hypothesis, the t-test indicates that any trend in these 





Figure 7: Activity of the PTEN promoter in A549 cells during Ad5 infection. 
Dual luciferase assays were performed in A549 cells transfected with the PTEN 
promoter-luciferase plasmid and Renilla luciferase followed by mock- or Ad5-
infection. This basic experiment was repeated 10 times. At 24 hours post-
transfection samples were either mock infected (black bars) or infected with Ad5 at 
300 vp/cell (grey bars). The lysates from each biological repeat were assayed in 
triplicate, and the mean firefly:renilla activity calculated. The mean firefly:renilla 
activity was normalised to the mock infected sample in each experiment. The error 
bars show +/- one standard deviation calculated from the 10 repeats. The raw data 
and standard deviations for each experimental repetition can be found in the 
Appendix (Table 1). 
The data shown in Fig. 7 were also analysed for percentage change in PTEN 
promoter activity in mock- and Ad5-infected A549 cells (Fig. 8). The majority of 
samples do not show a significant change in promoter activity, which is in 
agreement with the high p-values calculated by the student’s t-test. 
When comparing the percentage change in promoter activity between mock and 
Ad5 infected samples, it is likely that experiment 1 presents an anomalous result, as 
it does not fit the trend of the other 9 experiments, which all show a less pronounced 






















































Figure 8: PTEN promoter activity in A549 cells 24hpi is variable. The percentage 
change in PTEN promoter activity 24 hours post infection was calculated for each 
experiment, after the mean firefly:renilla activity had been normalised to mock 
infected samples.  
In certain experiments, lysates were also made using RIPA and protease inhibitors 
for use in Western blotting. Western blotting for the Ad5 protein, fibre, was analysed 
to demonstrate that virus replication had taken place 24 hours post-infection when 
samples were harvested for luciferase assays. Western blotting of the lysates was 
also used to monitor expression of PTEN protein in the mock and Ad5 infected 
transfected cell samples (Fig. 9).  
 
 
Figure 9: Ad5 infection in three experiments of the transfection/infection 
experiments in A549 cells. The presence of the late adenovirus fibre protein was 
detected by Western blotting of cell extracts (corresponding to 25μg of protein) 




























































luciferase plasmids. A rabbit polyclonal antibody was used against fibre, at 
concentration indicated in Table 4. Images were captured using a LAS3000 imager. 
The protein of approximately 62kDa detected with anti-fibre is a good indicator that 
Ad5 has entered and replicated within the cells in question. GAPDH was used as a 
loading control, and its presence at 38kDa in all lanes is an indicator that 
approximately equivalent masses of protein were analysed. As expected, PTEN was 
detected in all samples from transfected cells.  
 
Since no significant differences in PTEN promoter activity were detected between 
A549 cells that were either mock or infected with Ad5, this raised the question of the 
role of p53 in PTEN transcriptional regulation in Ad infection. P53 activates 
transcription of PTEN by directly binding to a p53 binding site in the PTEN promoter 
region (at -1190 to -1157 base  pairs upstream of the PTEN transcription start 
site)35. As p53 is targeted for proteasomal degradation by the Ad5 gene products 
E4orf6 and E1B55K during infection7, it is perhaps surprising that no decrease in 
PTEN promoter activity was observed during Ad5 infection. This question was 
addressed further using a p53-null cell line, H1299, for transfection and Ad5 
infection. 
 
4.3. The activity of the PTEN promoter in Ad5-infected H1299 cells  
Dual luciferase assays were performed in H1299 cells in the same way as 
performed in A549 cells. H1299 cells were co-transfected with the PTEN promoter-
luciferase plasmid and CMV-immediate early promoter-Renilla luciferase plasmid. 
Twenty-four hours post-transfection, samples were either mock infected or infected 
with Ad5 at 300 vp/cell. After a further 24 hours, samples were harvested, lysed with 
PLB and diluted appropriately for luciferase assay. All assays were performed in 
triplicate, and the mean firefly:renilla luciferase activity was calculated for each 
experiment, then was normalised to the mean firefly:renilla luciferase activity of the 
mock infected sample (Fig. 10). This basic experiment was repeated 9 times.  
A students’ t-test was performed on all the experimental repeats (n=9), to identify 
whether any overall difference between the PTEN promoter activity in mock or Ad5 
infected cells is statistically significant. The p-value calculated was 0.371, indicating 
any overall change observed in PTEN promoter activity following infection with Ad5 






Figure 10: PTEN promoter activity in mock and Ad5-infected H1299 cells. 
H1299 cells were transfected with a firefly luciferase gene under the control of the 
PTEN promoter region and co-transfected with Renilla luciferase as an internal 
control. At 24 hours post-transfection, samples were either mock (black bars) or Ad5 
infected (grey bars). Samples for luciferase assay were harvested 24hpi. The 
lysates from each biological repeat were assayed in triplicate, and the mean 
firefly:renilla activity calculated for both conditions in each experiment. The 
experiment was repeated on nine separate cell samples. To allow direct 
comparison, the values for Ad5 infected samples were normalised to the mock 
value. The error bars represent +/- one standard deviation calculated from the nine 
repeats. The standard deviation within the raw data for each repeat can be found in 
the Appendix (Table 2). 
 
The data shown in Fig. 10 were also analysed for percentage change in PTEN 
promoter activity in mock- and Ad5-infected cells (Fig. 11).  
When comparing the percentage change in promoter activity, it appears that there 
are two clusters of experiments. Biological repeats 1,2, 7 and 8 all show a less than 
25% increase in promoter activity in Ad5-infected H1299 cells, whereas biological 
repeats 4, 5, 6 and 9 show marked decrease in PTEN promoter activity in Ad5-


















































Figure 11: The percentage change of PTEN promoter activity between Ad5 and 
mock infected H1299 cells was highly variable. The percentage change was 
calculated from the mean renilla:firefly activity of each sample once normalised to 
the mock infected sample.  
 
To confirm Ad5 replication had taken place 24 hours after infection, in certain 
experiments lysates were also made using RIPA + PI for Western blotting. Samples 
from these experiments were analysed for the presence of the late Ad5 protein, 
fibre. If fibre is present in the Ad5 infected samples, this is an indicator that viral 
replication had occurred in these samples, and therefore any changes in luciferase 



























































Figure 12: Ad5 infection in three of the transfection/infection experiments in 
H1299 cells. The presence of the late adenovirus fibre protein was detected by 
Western blotting of cell extracts prepared from mock- and Ad5-infected H1299 cells, 
following transfection of luciferase plasmids. The volume of lysate corresponding to 
25μg of protein was loaded onto the gel, and protein was detected using a rabbit 
polyclonal antibody against fibre protein. Images were captured using a LAS3000, 
with HRP secondaries used for antibody detection. 
The presence of protein at 62kDa detected with anti-fibre in all three of the wells 
containing post-infection lysates indicates that Ad5 replication has occurred in the 
cells. GAPDH (which migrated at 38kDa) was using as a loading control to ensure 
equivalent masses of protein were loaded in each well. 
Overall, in H1299 cells, there was no significant difference in PTEN promoter activity 
between mock- and Ad5-infected samples. This tends to exclude p53 as a factor in 
regulating the PTEN promoter in Ad5 infection. 
4.4. Comparison of A549 and H1299 luciferase results 
To identify whether p53 status affects PTEN promoter activity during Ad5 infection, 
the luciferase assays results above, from a cell line with normal levels of p53 (A549) 







Figure 13: PTEN promoter activity in mock- and Ad5-infected A549 and H1299 
cells. The activity of the PTEN promoter was normalised to A) pGL3-basic, the 
negative control, and B) mock infected samples. The PTEN promoter activity was 
around twice as high in A549 cells compared to H1299 (when normalised to pGL3-
basic) but neither sample showed change to the PTEN promoter activity post 
infection. This indicates that p53 positively regulates PTEN transcription, but is not 
important in regulating PTEN promoter activity during Ad5 infection. As p53 
upregulates the activity of the PTEN promoter, the difference in PTEN promoter 
activity between the two cell lines is expected, due to the p53 null status of H1299 
cells. The error bars represent +/- one standard deviation for the data in each 
experimental condition. The p-values calculated from student’s t-tests performed on 
each cell line are shown above the respective bars.  
A students’ t-test was performed to identify if any difference in activity of the PTEN 
promoter in Ad5 infected A549 and H1299 cells is significant (n=10 for A549, and 
n=9 for H1299). The p-value equalled 0.602 when comparing A549 and H1299 cells, 
both of which had been transfected with the PTEN promoter-luciferase construct 
and infected with Ad5. 
Since no significant difference in PTEN promoter activity was detected post-infection 
in either H1299 or A549 cells, it might be informative to co-transfect H1299 with the 
PTEN promoter plasmid and a wild-type p53 expression plasmid to give a clearer 
indication as to whether p53 affects the activity of the PTEN promoter region during 
Ad5 infection. Such co-transfection experiment would mitigate for any differences in 





4.5. The effect of exogenous p53 expression on PTEN promoter activity during Ad5 
infection 
To identify whether p53 changes the activity of the PTEN promoter during Ad5 
infection, a co-transfection/dual luciferase assay was performed in H1299 cells, 
which are p53 null. H1299 cells were co-transfected with same PTEN 
promoter/firefly luciferase plasmid as above, with either a p53-containing plasmid or 
a pUC19 plasmid that acted as a negative control. pUC19 was used to ensure the 
same mass of DNA was being transfected in each condition, without impacting the 
luciferase activity of the samples. 
 
 
Figure 14: PTEN promoter activity in H1299 cells co-transfected with a p53 
expression plasmid or pUC19 and infected with Ad5. The PTEN + pUC19 
samples (black bars) reflect the luciferase activity in control H1299 cells infected 
with Ad5. PTEN promoter activity in H1299 cells co-transfected with a p53 
expression plasmid followed by Ad5 infection are shown by the grey bars. H1299 
cells were transfected with the same PTEN promoter-luciferase plasmid as before, 
as well as the Renilla luciferase plasmid. At 24 hours post-transfection, samples 
were either infected with Ad5 or mock infected, and after a further 24 hours, 
samples were harvested for luciferase assay. Assays were performed in triplicate, 
and the mean firefly:renilla luciferase activity calculated. Results are shown relative 
to the normalised luciferase activity of pUC19 co-transfected cells which is set to a 
value of 1. Three independent repeats of the experiment were performed. The error 





















































In one of the three experiments, restoration of p53 expression appeared to increase 
PTEN promoter activity in Ad5-infected cells. The remaining experiments showed 
very little difference in PTEN promoter expression between the H1299 sample and 
the p53-transfected H1299 sample. This could be due to inefficient transfection of 
p53, or Ad5 replication not being successful. 
 
Figure 15: Comparing change to the activity of the PTEN promoter post 
infection, dependent on the presence of p53. H1299 cells were transfected with 
the firefly luciferase gene under the control of the PTEN promoter region, which 
contains a p53 binding site. Samples were either co-transfected with p53 or pUC-19 
as a control, and infected or mock infected with Ad5. 24 hours post infection, cells 
were harvested, and the activity of the luciferase genes was measured. Transfection 
with RSV or pGL3-basic were used as the positive and negative controls, 
respectively. The error bars represent +/- one standard deviation of the data shown 
on the graph. 
 
In these experiments, Western blotting could not be used to detect a marker of Ad5 
infection or p53 expression. 
It was therefore decided to use cell lines in which there was targeted disruption of 
p53, and compare the luciferase activity in these cell lines following PTEN promoter-























































4.6. Further analysis of the effect of p53 on the activity of the PTEN promoter region 
during Ad5 replication 
HCT116+/+ is a cell line with normal expression of p53, for which a p53 knockout is 
available, termed HCT116-/- 88. Using cell lines where the only difference is the p53 
status enables the luciferase activity experiment to define the role of p53 in PTEN 
promoter activity during Ad5 infection. 
Transfection and infection were performed as above, with three independent 
experiments in each cell line used. Twenty-four hours after transfection, cells were 
either infected with Ad5 at 300 vp/cell, or mock infected. After a further 24 hours, 
cells were harvested with Passive Lysis Buffer, and the luciferase assay performed 
on the lysates. Each experiment was analysed in triplicate, and a mean value for 
firefly:renilla activity calculated from the triplicate repeats. 
 
Figure 16: Activity of the PTEN promoter region in mock- or Ad5-infected 
HCT116+/+ and HCT116-/- cells. Dual luciferase assays were performed on A) 
HCT116+/+ and B) HCT116 -/- cells transfected with a plasmid containing the firefly 
luciferase gene under the control of the PTEN promoter region. Renilla luciferase 
was co-transfected as an internal control. At 24 hours post-transfection, cells were 
either mock infected or infected with Ad5 at 300vp/cell. A further 24 hours later, cell 
lysates were harvested. The error bars represent +/- one standard deviation of the 
data shown on the graph. 
A students’ t-test was performed on the three experimental repeats (n=3), after 
normalisation to mock infected samples, and p= 0.06 for HCT116 +/+ cells. Although 
this p-value is closer to the 0.05 value indicating statistical significance, it is still too 
high to give confidence that differences in PTEN promoter activity shown in these 




HCT116-/- samples was 0.68, further confirming that any difference in PTEN 
promoter activity was not statistically significant within this cell line.  
4.7. Comparing PTEN promoter activity in HCT116+/+ and HCT116-/- cells 
The activity of the PTEN promoter in both HCT116+/+ and HCT116-/- was 
compared to identify whether the p53 status of the cells affected PTEN promoter 
activity in Ad5 infected samples. 
 
Figure 17: PTEN promoter activity in either mock- or Ad5-infected HCT116+/+ 
and HCT116-/- cells. Cells were transfected with the PTEN promoter-luciferase 
constructs and a Renilla plasmid. After 24 hours, cells were either mock infected or 
infected with Ad5 at 300vp/cell. A further 24 hours later, cells were detached and 
lysed with PLB. Dual luciferase assays were performed in triplicate on the cell 
lysates, and the mean firefly:renilla activity for each sample calculated. This basic 
experiment was repeated three times for each cell, and the average of the mean 
firefly:renilla activity calculated and normalised to the mock value. 
A students t-test was performed to compare the significance of any difference in 
PTEN promoter activity in Ad5-infected HCT116+/+ and HCT116-/- cells (Fig. 17). 
The calculated p-value was 0.510, indicating that any difference in PTEN promoter 









4.8. Collating all luciferase results  
The results of the luciferase experiments in each cell line were collated into a table 
for easy comparison. The p53 status of each cell line or experimental condition has 
been noted, along with the p-value calculated by a student’s t-test on the biological 
repeats performed in each cell line. None of the cell lines show significant difference 
between the luciferase activity in mock and Ad5 infected cells, indicating that the 
p53 status of the cell line does not impact the activity of the PTEN promoter during 
Ad5 infection. 
Table 6: The luciferase activity of all cell lines used for assays. The values given are 
the mean of the biological repeats of each cell line for each condition, all normalised 
to the mock value in each cell line. The p-value was calculated using a student’s t-
test. For A549, n=10, for H1299 n=9, and for H1299+p53, HCT116+/+ and   




Cell line p53 status mock Ad5 p-value 
A549 + 1 0.990061 0.922 
H1299 - 1 0.91808 0.371 
H1299+p53 + 1 0.797343 0.45 
HCT116+/+ + 1 0.924987 0.063 















5. Construction and molecular characterisation of PTEN-expressing 
U87MG cell lines 
5.1. Production of a PTEN-retrovirus and transduction of U87MG cells 
The retroviral transduction method of establishing stable transgene expression 
exploits the ability of a retrovirus to integrate its genetic material into the host cell 
DNA. Phoenix Ampho cells produce the retrovirus proteins derived from the gag, pol 
and env genes. However, Phoenix Ampho cells are unable to package RNA into 
viable retroviruses due to mutation of the packaging signals in the retroviral genome. 
By transfecting the Phoenix Ampho cells with a pBABE plasmid containing a gene of 
interest flanked by wild-type packaging signals and a selectable marker, this gene is 
incorporated into the retrovirus which, on subsequent transduction of human cells,  
is reverse transcribed and integrated into the cellular genome. The selectable 
marker permits selection of stably integrated retroviral genomes.  
The plasmid was analysed by electrophoresis on an agarose gel to confirm the 
presence of plasmid DNA. This confirmed the presence of plasmid DNA in the midi-
prep. The PTEN insert in the pBABE plasmid was sent for sequencing by GeneWiz 
and analysis of the sequencing results showed a greater than 99% percentage 
identity with various retroviral vectors, and a 100% identity to PTEN mRNA 






Figure 18: Analysis of the pBABE-PTEN plasmid by agarose gel 
electrophoresis. Plasmid (0.5μg) was separated by electrophoresis on a 0.75% 
agarose gel at 100V for an hour, then visualised using an FLA5000 imager. 
SybrGreen was added to the gel to enable visualisation of the DNA. The expected 
size of the plasmid was around 6300 bp. There are 3 bands present on the gel, due 
to the different migration rates of different plasmid conformations. The highest band 
on the gel is likely to be nicked, open circular plasmid, which migrates slowly. The 
middle band at approximately 8kDa is most likely linear plasmid, and the lowest 
band may be supercoiled plasmid, which migrates the fastest through the gel88. 
The pBABE-PTEN plasmid was transfected into Phoenix Ampho cells using 
Lipofectamine 2000, and the resulting virus harvested. This virus was used to 
transduce U87MG cells. Puromycin resistance was used as the selectable marker, 
and after transduction, cells were maintained in puromycin-containing medium. 
 
5.2. Detection of PTEN in transduced cells 
After U87MG cells were transduced with the PTEN gene by retroviral transduction, 





It had previously been established that U87MG is PTEN-null and, as expected, no 
band was present at 57kDa in the Western blot with anti-PTEN antibody that could 
correspond to PTEN. A549 cells express normal PTEN and a 57kDa protein was 
detected by Western blotting with anti-PTEN. The band in the lane corresponding to 
a sample of the U87MG cells transduced with the PTEN  retrovirus (U87MG/PTEN) 
is a good indication that the retroviral transduction performed as described in 
Methods was successful, and the pool of U87MG cells expressed PTEN at a level 
similar to that of A549 cells.   
 
Figure 19: PTEN expression in U87MG, A549 and the transfected U87MG pool. 
To compare levels of PTEN protein in the PTEN-transduced U87MG pool, a 
Western blot was performed on the volume of lysate corresponding to 25μg of 
protein in U87MG, A549 and the pooled U87MG/PTEN cells, using an anti-PTEN 
antibody (Cell Signalling Technology) (Fig. 19). Detection of GAPDH served as a 
loading control, to ensure equivalent masses of protein were loaded in each sample. 
To isolate clonal populations of PTEN-expressing U87MG cells, limiting dilution was 
performed, and the resulting populations expanded into wells of 6-well plates. 
Clones were named after the well of the 6-well plate from which they were taken (A1 
through 6 and B1 through 6). Levels of PTEN between the clones was variable and 
was quantified by normalising to the level of GAPDH present in the sample. The 
clones with the most similar level of PTEN to A549 were considered for further 






Figure 20: Levels of PTEN protein in U87MG/PTEN clones. Cell lysates were 
harvested, and protein content resolved by SDS-PAGE. Once transferred to a PVDF 
membrane, lysates were tested using anti-PTEN (1:1000, Cell Signalling 
Technology) and anti-GAPDH (1:1000) with the corresponding HRP secondary to 
allow imaging.   
25μg of protein per sample as calculated by BCA assay was loaded onto the gel. 
Blotting with anti-GAPDH as a loading control illustrated that more protein was 
loaded for A549, U87MG and U87MG/PTEN A6 than the other “A” clones. Loading 
of the U87MG/PTEN “B” clones was fairly even, save for clone B5. Densitometry 
analysis was performed on each sample, with the PTEN band isolated using Fujifilm 
Multi-Gauge software and normalised to the isolated GAPDH band for each sample 


















Table 7: Comparing PTEN protein levels in U87MG/PTEN “A” clones with A549. 
Cell Line PTEN/GAPDH signal 
compared to A549 
Ranking PTEN 



















Table 8: Comparing PTEN protein levels in U87MG/PTEN “B” clones with A549. 
Cell Line PTEN/GAPDH signal 
compared to A549 
Ranking PTEN 























PTEN-expressing U87MG clones were carried forward for further analysis based on 
the similarity of PTEN protein levels when compared to A549. U87MG/PTEN B5 
was discounted as the level of PTEN was lower than that of A549. Clones B6, B4 
and B1 were carried forward for immunofluorescence.  
Immunofluorescence analysis enables the proportion of PTEN-expressing cells 
within each cell line to be estimated and gives an indication of the localisation of 
PTEN within the cells. 
5.3. Immunofluorescence analysis of PTEN in A549 and U87MG 
Figure 21: Initial immunofluorescence of U87MG and A549 cells for anti-PTEN. 
A) U87MG cells and B) A549 cells were fixed with methanol and stained for PTEN, 
then imaged using an EVOS microscope at a 20x magnification. Nuclei were stained 
with DAPI, shown in blue. Immunofluorescent antibody staining was performed 
using a mouse monoclonal anti-PTEN (SantaCruz) at 1:100 dilution, with secondary 
AlexaFluor-488-labelled goat anti-mouse at 1:1000 dilution. 
This experiment identified an issue with the antibodies used. As U87MG is a PTEN-
null cell line, there should have been no green fluorescence present corresponding 
to PTEN. However, as seen in the images above, the U87MG cells were fluorescing 
green to a degree not explained by background fluorescence. The levels of 
fluorescence present meant estimating the proportion of the U87MG/PTEN 









5.4. Characterising the Santa Cruz and Cell Signalling Technology anti-PTEN 
Antibodies 
 
Figure 22: Immunofluorescence of PTEN in A549 and U87MG cells to compare 




As established previously, the Cell Signalling (CST) anti-PTEN antibody shows one 
clear band at approximately 47kDa in A549 cells on a Western blot. To identify if the 
Santa Cruz (SC) PTEN antibody forms non-specific interactions in any of the cell 
lines used for IF, a Western blot was performed on the cell lysates using Santa Cruz 
anti-PTEN. 
Figure 23: Western blot analysis of the Santa Cruz anti-PTEN antibody.  
The Western blot shown in Figure 23 revealed additional bands in U87MG and 
PTEN-expressing U87MG cell lysates, but not in A549. As the additional bands 
were located at the very top of the gel, it is difficult to identify whether said bands 
were an artefact or non-specific binding that might cause the fluorescence in 
U87MG cells noted in Figure 23. 
As these higher molecular mass bands were more intense than the band at the 
expected molecular mass of PTEN, it is important to ascertain what they represent. 
A 10% acrylamide gel followed by Western blotting was therefore performed on the 





Figure 24: Further comparison of the Santa Cruz and Cell Signalling 
Technology antibodies by Western blotting following electrophoresis in a 10% 
acrylamide gel. 
The higher molecular mass bands detected in U87MG and PTEN-expressing 
U87MG cell lines with the Santa Cruz PTEN antibody migrated into the 10% gel. 
This indicates that the bands in the blot shown in Figure 23 are not artefacts but 
may, instead, be a result of interactions of the antibody with an unidentified protein 
within the U87MG and U87MG-derived cell lines. These bands were not detected 
when the CST anti-PTEN was used, and therefore  may represent non-specific 
binding of the Santa Cruz antibody to other proteins in U87MG cells. 
Alternatively, these additional proteins may be  caused by the Santa Cruz antibody 
binding to PTEN-long, another epitope of PTEN present in certain human cell lines. 




5.5. Immunofluorescence of U87MG/PTEN clones for PTEN protein 
To visualise the proportion of each cell population that was expressing PTEN, immunofluorescent staining of PTEN was performed, with DAPI 
used to locate the nucleus of each cell. Immunofluorescence also gave an indication of the localisation of PTEN within the cell. 
Figure 25:  Characterisation of  PTEN protein expression in U87MG/PTEN clones.  Cells were fixed with methanol, and 
immunofluorescence analysis performed using CST anti-PTEN at 1:100 dilution with secondary AlexaFluor-488-labelled goat anti-rabbit at 




The number of PTEN-expressing cells within each population was counted from around 100 
cells per clone. U87MG/PTEN B1 was expressing PTEN to the same degree as A549 (or 
higher) in  77% of cells, and U87MG/PTEN B4 expressed PTEN to the same degree  as 




5.6. Infection of PTEN-expressing U87MG cells. 
Given that Ad5 is unable to replicate efficiently in U87MG yet replicates in A549 -a cell line 
with normal PTEN- it is of interest to elucidate whether restoring PTEN protein to U87MG 
cells will restore the ability of Ad5 to replicate.  
Once the presence of PTEN in the transduced clones was confirmed, the clones B1, B4 and 
B6 were infected with Ad5, alongside U87MG and A549 as negative and positive controls for 
PTEN, respectively. Western blotting was performed on infected cell lysates to identify the 
level of viral protein produced, with immunofluorescence also being employed to visualise 
the cellular localisation of the viral proteins.  
5.6.1. Detecting viral protein in infected cells 
 
                                                                                                                                                        
Figure 26: Expression of early viral proteins in mock and Ad5 infected cells. Samples 
were probed using anti-E1A (1:1000) and anti-72K (1:5000) and their respective HRP 
antibodies. The two groups of bands in the E1A blot are representative of the multiple 
phosphorylated protein species encoded by E1A, of 243 and 289 amino acids. The two 
bands in each division are representative of phosphorylated derivatives of the E1A proteins. 
The second early virus protein detected is the 72K DNA binding protein, which is detected at 
the expected 72kDa in all infected samples. Anti-GAPDH (1:10000) was used as a loading 
control, with 25μg of protein being loaded per sample.  
In conjunction with the early viral proteins, the samples were also tested for the presence of 





Figure 27: Expression of the late viral proteins-fibre and penton-in Ad5 infected cells. 
Owing to the large quantities of viral protein present, the amount of protein loaded onto the 
gel was decreased to 10μg per sample. Cell lysates were tested using rabbit anti-fibre 
(1:2000) and rabbit anti-penton base (1:1000), with rabbit anti-HRP used as the secondary 
antibody. Protein was imaged using a LAS3000 imager.  
Protein bands at around 62kDa are present in infected samples when blotting with anti-fibre, 
with a lesser amount present in the infected U87MG/PTEN clones. The density of the protein 
bands in infected lysates at around 63kDa when blotting for anti-penton base are consistent 







Figure 28: Expression of PTEN in mock and infected cells. The presence of PTEN was 
also tested for in mock and infected cells, to identify whether the 50% decrease in PTEN 
protein following infection observed by previous members of the Blair group also occurs in 
the PTEN-expressing U87MG cell lines.  
Densitometry analysis of these blots was performed using FujiFilm Multi-Gauge software. 
The bands for each viral protein were isolated and normalised to the respective GAPDH 
band for each sample. 
Table 9: Densitometry analysis of protein levels in infected cell lines. Cells were 
infected with virus at 300vp/cell, then harvested 24 hours post infection. Bands were isolated 
using FujiFilm MultiGuage software and normalised to the density of the corresponding 
GAPDH band.  
 
Viral protein normalised to GAPDH 
Cell line E1A 243 E1A 289 72K higher 72K lower penton fibre 
A549 0.69 1.09 1.46 1.30 4.37 1.17 
U87MG 0.69 1.12 1.41 1.11 1.53 1.07 
U87MG/PTEN 
B1 
0.68 1.04 1.51 1.29 3.25 0.72 
U87MG/PTEN 
B4  
0.45 0.88 0.98 0.66 9.86 3.50 
U87MG/PTEN 
B6  






Figure 29: Comparing viral protein levels in A549, U87MG and U87MG/PTEN cell lines. 
The level of A) E1A proteins, B) 72K proteins, C) fibre protein and D) penton base protein 
present in each cell line 24 hours post infection was isolated by Western blot and normalised 
to the level of GAPDH within each sample.  
These results were unexpected as there appeared to be little difference between the level of 
viral protein expressed in U87MG cells and A459 cells, which did not conform with previous 
results by the Blair group. Additionally, there was no consistency within each infected 
U87MG/PTEN cell line as to whether viral protein has increased or decreased when 












5.6.2. Immunofluorescent antibody staining of Ad5 proteins in infected cells 
A) Infection of A549 cells 
 
 
Figure 30: Immunofluorescence imaging of Ad5 infected and mock infected A549 cells. 
Cells were infected with virus at 300vp/cell, and incubated for 24hours at 37°C. During 
fluorescence staining, the viral proteins were labelled with an Alexa-Fluor 488 secondary 
antibody, which fluoresced green. The nucleus of the cells was labelled with DAPI , which 
fluoresced blue. Primary antibodies were used at the following concentrations: E1A at 1:100, 
DBP at 1:10, fibre at 1:2000 and penton at 1:1000. Cells were scanned using a 20x objective 
by an EVOS microscope. 
E1A was present in lower levels than the other viral proteins, and did not form notable 
structures. DBP formed granular structures, localised to the nucleus. Fibre formed a 
combination of linear and granular structures, localised to the periphery of the nucleus. 
Finally, penton also formed a combination of linear and granular structures, and was located 











B) Infection of U87MG cells 
Figure 31: Immunofluorescence imaging of U87MG cells that had either been mock 
infected or infected with Ad5. Cells were infected with Ad5 at 300vp/cell, then incubated at 
37°C for 24 hours. Imaging was performed at a 20x magnification, with DAPI (blue) used to 
locate the nucleus. The viral proteins were imaged using an Alexa-Fluor488 secondary 
antibody, and therefore fluoresced green. Unlike A549 cells, where the majority of cells 
exhibited fluorescence for each viral antibody, U87MG cells presented with bright “hotspots” 
of fluorescence in few cells. Little in the way of structures formed by viral proteins could be 
ascertained. 
 
C) Infection of U87MG/PTEN cell lines 
PTEN-expressing U87MG cell lines were infected with Ad5 at 300 vp/cell. Twenty-four hours 
post-infection, cells were fixed with methanol and stained using the four viral antibodies (as 
in figure 31) and DAPI. Images were taken at a range of magnifications, to identify a 
proportion of cells positive for viral protein, and to identify the localisation of the viral protein 





i) Infection of U87MG/PTEN B1 
Figure 32: Immunofluorescence analysis of virus proteins in Ad5-infected U87MG/PTEN B1 cells. Immunofluorescence was performed 
24 hours after cells were infected with Ad5 at 300vp/cell. DAPI (blue) was used to locate the nucleus, and the appropriate virus protein antibody 
with an AlexaFluor-488 anti-goat secondary was used to show the virus protein (green). Primary antibodies were used at the following 





ii) Infection of U87MG/PTEN B4 
Figure 33: Viral protein in infected U87MG/PTEN B4 cells, shown by fluorescence microscopy. Cell were incubated with the viral 
antibodies at appropriate dilutions, and Alexa-Fluor488 was used as the secondary antibody. Viral proteins were shown in green, and DAPI, 
which localises to the nucleus, was shown in blue. Cells were scanned using either a 10x or 40x objective. 
Unlike infected A549 cells,  infected U87MG/PTEN B4 cells showed sparse fluorescence for early viral proteins E1A and 72K. A small 
proportion of the cells present exhibited green fluorescence, as shown by the 10x objective. When the same samples were viewed with a 40x 




Additionally, similar to infected U87MG cells, very few of the U87MG/PTEN B4 cells showed green fluorescence for the late viral proteins, fibre 
and penton. Where fibre and penton were present, it is in “hotspots”, where the green fluorescence was highly concentrated to a single cell, 
and the brightness of the microscope used was adjusted to accommodate this. 
iii) Infection of U87MG/PTEN B6 
 
Figure 34: Viral protein in Ad5 infected U87MG/PTEN B6 cells, shown by fluorescence microscopy. The antibodies for the viral proteins 
were used as primary antibodies, with Alexa Fluor-488 used as the secondary. Viral proteins will therefore fluoresce green, and DAPI 




U87MG/PTEN B6 cells infected with Ad5 show very little evidence of viral replication by fluorescence microscopy. In the cells treated with anti-
72K, some green fluorescence was captured at a 10x objective, but the vast proportion of cells showed no fluorescence. Of interest for future 
work may be the co-staining and immunofluorescence of PTEN and the viral proteins. 
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5.7. Transduction of cells with Ad5EGFP 
To ascertain whether Ad5 entered the PTEN-expressing U87MG cell lines, the cell 
lines were transduced with a replication-deficient Ad5-EGFP virus, where an EGFP 
gene replaced the E1A and E1B genes. Therefore, EGFP is used as a marker for cell 
entry and migration of virus to the nucleus where the EGFP transgene is transcribed. 
The newly-synthesised EGFP was viewed by fluorescence microscopy. 
 
Figure 35: Entry of Ad5EGFP into A549 and U87MG cells. Cells were infected with 
















Figure 36: Ad5EGFP entry into PTEN-expressing U87MG cell lines. Cells were 
transduced with virus at 600vp/cell, incubated for 24 hours, then imaged using an 
EVOS microscope. 
Flow cytometry was performed on PFA-fixed mock and Ad5EGFP infected cell lines, to 
quantify the successfully transduced cells. Gates were set around an unlabelled control 
sample, then an additional gate was set using each mock sample to isolate cells 























Figure 37: Quantification of cell entry by Ad5EGFP. A) A549, B) U87MG, C) 
U87MG/PTEN B1, D) U87MG/PTEN B4, Cells and E) U87MG/PTEN B6 cells were 
transduced with Ad5EGFP at 600vp/cell and incubated for 24 hours. Cells were 
detached from the plate, fixed with 4% PFA and analysed by flow cytometry. 













Table 10: Quantification of cell entry by Ad5EGFP. 
 Percentage EGFP positive cells Percentage 
transduced cells 
Cell Line Mock Ad5  
A549 0.89 64.65 63.76 
U87MG 0.73 68.37 67.64 
U87MG/PTEN B1 3.60 51.57 47.97 
U87MG/PTEN B4 0.08 62.17 62.09 
U87MG/PTEN B6 0.04 58.92 58.88 
 
All cell lines except U87MG/PTEN B1 were successfully transduced with Ad5EGFP 
where over half of cells were expressing EGFP at 24 hours post-transduction. The 
similar values for A549 and U87MG was expected, as indicated by previous work by 
the Blair group. However, it was expected that A549 cells would be more highly 
transduced than U87MG. It could be that a proportion of successfully transduced cells 
were removed during the washing step, resulting in smaller percentages of transduced 





















6.1. Regulation of the PTEN promoter during Ad5 infection 
PTEN regulation is highly complex, with regulation of protein expression occurring at 
the transcriptional, translational and post-translational level.  
Previous work in the Blair group has found a 50% reduction in PTEN protein during 
Ad5 infection, and this project aimed to identify whether the cause for this reduction is 
transcriptional regulation of PTEN.  
Numerous cellular factors are able to regulate PTEN transcription, both positively and 
negatively. P53, for example, is known to upregulate PTEN transcription by directly 
binding to the PTEN promoter region.  
6.1.1. The PTEN promoter region 
The PTEN promoter region is a GC-rich, TATA-less region with multiple transcription 
start sites89. A minimum promoter region has been identified at -958 to -821 base pairs 
from the ATG start codon of the PTEN protein, which contains consensus binding sites 
for numerous transcription factors, including GATA1, GATA2, and Dof3 (a single zinc 
finger transcription factor)89. Direct binding of transcription factors such as p5335 and 
c-Jun42 to the PTEN promoter region have been implicated in regulation of PTEN 
transcription. 
Of particular interest to this project is the regulation of PTEN transcription by p53. Wild-
type p53 is known to upregulate PTEN transcription35 and is targeted for proteasomal 
degradation by adenovirus proteins E1B-55K and E4orf67. Thus, a decrease in p53 in 
Ad5 infected cells may cause a decrease in activity at the PTEN promoter, leading to 
the decrease in PTEN mRNA and protein identified by previous members of the Blair 
group. 
However, the transient expression of PTEN promoter-luciferase plasmids and 
subsequent luciferase assays performed demonstrate that there was no significant 
change to the activity of the PTEN promoter during Ad5 infection in various cell lines, 
both p53-positive and p53-null, which indicates that the 50% decrease in PTEN protein 
and mRNA previously detected during Ad5 infection was not caused by a decrease in 
promoter activity. Instead, it may be caused by virus-mediated post-transcriptional 
mRNA processing or degradation, as PTEN mRNA is also decreased by 50%. Viruses 
are able to directly target host proteins or can manipulate host systems such as miRNA 
regulation of mRNAs and hence steady-state levels of protein. Adenoviruses are able 





different miRNAs, it is possible that virus-mediated dysregulation of host miRNAs leads 
to the lowered level of PTEN mRNA. 
6.1.2.  miRNA regulation of PTEN 
Alongside transcriptional and post-translational regulation of PTEN, PTEN can also be 
regulated by microRNAs (miRNAs). miRNAs target mRNAs through complementary 
base pairing of the ‘seed’ region of the miRNA to the mRNA. The miRNA can then 
either destabilise the mRNA or inhibit its translation47. miRNAs can bind to multiple 
targets, and work in conjunction with one another91. 
PTEN is known to be regulated by miRNAs in a largely cell-type specific manner. miR-
21, for example, has been identified as a negative regulator of PTEN in gastric cancer, 
head and neck squamous cell carcinoma92 and clear cell renal cell carcinoma. Further 
examples of negative PTEN regulators include miR-130 in lung adenocarcinoma and 
bladder cancer93, miR-221/222 in non-small cell lung cancer94, miR-301a in breast 
cancer95 and melanoma96, and miR-155-5p in hepatocellular carcinoma97. PTEN can 
also be upregulated by miRNA, either by direct targeting of the PTEN mRNA or by 
miRNA mediated upregulation of hypomethylation of the PTEN promoter region49.  
6.1.3. miRNA dysregulation by Adenovirus infection 
During Adenovirus infection, host miRNAs are targeted to dysregulate the cell cycle 
and thus create an environment conducive to viral replication91.Adenovirus infection 
has been noted to deregulate host miRNAs in stages, similar to the dysregulation of 
host genes. In stage 1 of viral infection (0-12 hours post-infection), miRNAs with roles 
in the host immune response such as miR-22, miR-181b, miR320 and let-7e are 
upregulated98. 
In the second stage of infection (hours 12-24 post-infection), the cell environment 
begins to change as host gene expression is altered by the presence of the viral E1A 
protein. At this timepoint, additional miRNAs involved in the host immune response are 
upregulated, and the first virus-mediated down-regulation of host miRNA is observed. 
The downregulated miRNAs are largely tumour suppressive miRNAs, such as miR-34a 
and miR-185. There is also an upregulation in a small number of oncogenic miRNAs 
(miR-21 and the miR-17/92 cluster) at this timepoint, believed to be a cell response to 
combat viral replication98.   
In the late stages of viral replication (24 hours post-infection onwards), previously 
overexpressed host miRNAs involved in the immune response are downregulated, 
alongside oncogenic miRNAs miR-193 and miR-221. Whether the downregulation of 






At 36 hours post-infection onwards, there is a marked deregulation of both host genes 
and miRNAs, with around 146 host miRNAs being differentially expressed by over 1.5 
fold compared to mock samples98. These data for miRNAs dysregulated in Ad 
infection comes from experiments with Ad2, these data may be somewhat similar to 
Ad5 infection, as both Ad5 and Ad2 belong to species C of the human Adenoviruses.  
The cell-type specificity of PTEN regulation by miRNAs does make analysis of the 
literature difficult, but we can identify potential miRNAs of interest by looking at any 
overlap in miRNAs involved in the regulation of PTEN and those that are dysregulated 
during Adenovirus infection.  
By comparing miRNAs that regulate PTEN with miRNAs dysregulated in Ad infection, 
numerous miRNAs of interest can be identified.  
Table 11: Comparing miRNAs that regulate PTEN and are dysregulated during Ad 
infection. 
Regulates PTEN Dysregulated during Ad infection 
Upregulates PTEN  
miR-29 
miR-185 

















For example, miR-155-5p is known to downregulate PTEN mRNA49,97, and is also 
subjected to change in expression during Ad infection98. Initially, miR-155-5p 
expression is increased during Ad infection, but after 24hpi, expression decreases98. 
The increase in miR-155-5p during the early stages of infection may therefore 
contribute to the decrease in PTEN mRNA and protein. MiR-130a is also a known 
downregulator of PTEN expression, and is upregulated at 24 hours post-infection with 
adenovirus98. As with miR-155-5p, the downregulatory effect of miR-130a on PTEN 
may contribute to the decrease in PTEN protein observed.  
miR-29a is a positive regulator of PTEN expression that functions by inhibiting DNA 





the host immune response to Ad infection, then downregulated99, which may affect the 
level of PTEN in the cells. 
An additional consideration is the role of viral miRNAs on the expression of host 
miRNAs. 
6.1.4. Adenovirus miRNAs 
Adenovirus genomes encode for one or two non-coding RNAs (ncRNAs). The first is 
VARNAI which is present in all Adenovirus types, and the second is VARNAII, which is 
present in around 80% of Ad types91. Although the length of the VA RNAs is similar 
(157-160 nucleotides for VA RNAI and 158-161 nucleotides for VA RNAII) and the 
presence conserved 5’ and 3’ terminal sequences, the nucleotide sequences of the VA 
RNAs are diverse, both within a specific virus type and between species90. VA RNAs 
deregulate host miRNA processing through binding and sequestration of DICER, the 
complex that produces mature miRNAs from pre-miRNAs90,91. VA RNAs can also 
saturate Exportin-5, which exports host pre-miRNAs from the nucleus91. This 
disruption of the miRNA biogenesis pathway by VA RNAs may contribute to the 
reduction in PTEN during Ad5 infection. 
VA RNAs contribute to viral deregulation of host proteins, and 462 genes have been 
shown to be downregulated following transfection of cells with VA RNAI and VA RNAII, 
a large proportion of which have complementary sequences to the seed region of 
mivaRNAs99. The downregulated genes performed roles in cell signalling, cell growth 
and apoptosis control as well as DNA repair.  
VA RNAs are processed in a similar way to host miRNAs, through cleavage by DICER 
to produce viral-associated microRNAs (mivaRNAs). The mivaRNAs can occupy RISC 
complexes, contributing to the post-transcription downregulation of host gene 
expression100. The high abundance of mivaRNA isoforms means identifying and 
verifying direct targets of mivaRNAs is difficult. 
 
6.2. Role of PTEN in Adenovirus Replication 
A PTEN-expressing variant of U87MG cells was created to enable cell-type specific 
analysis of the role of PTEN expression in Adenovirus infection. As mentioned above, 
PTEN is regulated by a very complex system, and the prevalence of different 
regulatory mechanisms may differ between cell types.  
The Western blots for viral proteins expressed following infection of U87MG/PTEN 
clones showed a reduction in viral protein expression for the majority of viral proteins in 





unexpected result, firstly because previous findings by the Blair group illustrated a 
significant decrease in Adenovirus proteins between A549 and U87MG. The level of 
penton base in Ad5-infected U87MG cells was 5% that of the penton base level in 
infected A549 cells, and fibre had decreased to 30% of the level of A549 cells in 
U87MG cells. Similar differences were seen in the early Adenovirus proteins E1A and 
DBP.  
Secondly, previous findings that Adenovirus proteins are expressed at a lower level in 
infected A549 cells with reduced PTEN levels led to the construction of a hypothesis 
that restoration of PTEN expression in a normally PTEN-null cell line may restore the 
ability of Ad5 to replicate. It was therefore expected that an increase in virus protein 
would be observed between U87MG and the PTEN-expressing clones. This was 
observed in some instances, for example, the U87MG/PTEN clone B4 exhibited a 6.4 
and 3.3 fold increase in penton base and fibre protein, respectively, when compared to 
U87MG. However, a corresponding increase in early viral proteins was not observed, 
calling into question the validity of these results. 
Overall, the Western blot analysis of infection gives no consensus as to whether 
restoring PTEN expression to U87MG cells affects the replication of Ad5. 
Of interest is the similarity between localisation of viral proteins illustrated by IF in 
U87MG and the PTEN-expressing clones, although high-resolution imaging would be 
needed to confirm this. Both normal U87MG and U87MG/PTEN clones show an 
uneven distribution of viral proteins (both early and late), with very little fluorescence 
except in intense “hotspots”. The PTEN-expressing clones appear to have less viral 
protein present than U87MG by immunofluorescence. This may indicate that the role of 
PTEN in Adenovirus infection is not as significant as expected, and that another 
difference between the cell lines is responsible for the differences in adenovirus 
replication previously identified by the Blair group.  
Alternatively, if the transduced PTEN protein is not functional, this might account for the 
similarity between U87MG and U87MG/PTEN cell lines. To clarify this, a Western blot 
against phospho-AKT in U87MG and U87MG/PTEN cell lines would be useful, as if the 
transduced PTEN is functional, a decrease in phospho-AKT would be observed. 
Previous work (Painter, unpublished results) had identified that reducing PTEN protein 
levels by around 70% by RNA interference caused a decrease in both early and late 
Adenovirus proteins following infection. Penton base protein levels were reduced by 
70% and fibre was reduced by around 50% in the reduced-PTEN A549. Similarly, DBP 
and E1A were reduced by around 40% and 50% respectively. It would therefore be 





test for viral protein expression following Ad5 infection. If virus proteins were similarly 
expressed in PTEN-null A549 and U87MG cells, then this would be a good indicator 































7. Conclusions and Future Directions 
Adenoviruses are pathogens which have the capacity to cause life-threatening illness 
in the immunocompromised101. Confirming that PTEN is necessary for Adenovirus 
infection would provide a potential avenue for anti-virals as by inhibiting PTEN, viral 
replication would also be inhibited. This project has not been able to ascertain whether 
Ad5 infection is dependent on PTEN status, but additional work to confirm that PTEN is 
functional in the U87MG/PTEN cell lines would be beneficial to this regard. In addition, 
designing a PTEN-knockout A549 cell line using Crispr-Cas technologies would enable 
further analysis of the role of PTEN during Ad5 infection. Having the PTEN-knockout 
A549 cell line would enable the isolation of the role of PTEN, as currently it is not 
known whether the cause for poor Adenovirus replication in U87MG is the PTEN-null 
status or the role of another cellular factor. Furthermore, relatively specific, reversible 
PTEN inhibitors are available, such as bisperoxovandium compound 
bisperoxovanadium 1, 10-phenatroline102. It would be of interest to use these 
inhibitors to identify whether the catalytic activity of PTEN is required for Adenovirus 
replication in A549, as a decrease in PTEN by RNA interference led to a decrease in 
virus replication.  
Gaining an understanding of how PTEN is regulated and the role it plays in Adenovirus 
replication has potential implications for both oncolytic adenovirotherapy as well as the 
development of anti-virals. Ad5-based vectors are being studied more frequently as 
cancer therapeutics103,104, and therefore it is important to understand whether the 
PTEN-null status of U87MG cells is the limiting factor to Ad5 replication, so that 
oncolytic virotherapies targeting PTEN-null cancers can be modified to combat the poor 
replication observed.  
 
The possibility that PTEN regulation by p53 is significant during Adenovirus infection 
has also been investigated. We found no significant change in PTEN promoter activity 
following Ad5 infection, in both wild-type p53 and p53-null cell lines, indicating that 
although p53 does positively regulate PTEN transcription35 (Figure 13), this regulation 
of PTEN is not affected by Ad5 infection (Figures 13, 14 and 16) . This therefore opens 
the field of investigation to the role of miRNAs in regulating PTEN during Ad5 infection. 
Identification of miRNas that both regulate PTEN and are dysregulated by Adenovirus 
infection provides a starting point for screening which miRNAs may be responsible for 
the 50% decrease in PTEN mRNA and protein previously observed by the Blair group. 
Inhibition of specific miRNAs by Anti-miRs105 could provide insight into which of the 
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9. Appendix 
Table 1: Luciferase assays in A549 
  







Replicate mock Ad5 mock Ad5 mock Ad5 T-test mock Ad5 
1 1 0.035383 0.014849 0.028383 0.013273 0.00495 0.001968 0.015974 1 0.467617 
2 0.024816 0.014472 
3 0.024951 0.010498 
2 1 0.076853 0.029346 0.074695 0.02994 0.004557 0.001282 0.000181 1 0.400827 
2 0.078875 0.031721 
3 0.068357 0.028753 
3 1 0.011033 0.00997 0.013206 0.010615 0.001538 0.000457 0.084306 1 0.803742 
2 0.014234 0.010901 
3 0.014352 0.010973 
4 1 0.00743 0.00625 0.006785 0.006222 0.000577 0.000237 0.27052 1 0.916978 
2 0.00603 0.006497 
3 0.006897 0.005919 
5 1 0.003753 0.004236 0.004672 0.007117 0.000982 0.00341 0.385152 1 1.523133 
2 0.006033 0.011906 
3 0.004231 0.005208 
6 1 0.001345 0.003094 0.001927 0.003222 0.000412 0.000519 0.050743 1 1.672256 
2 0.002177 0.002659 
3 0.002257 0.003912 





2 0.007667 0.010913 
3 0.007835 0.010597 
8 1 0.008571 0.011305 0.008684 0.010945 0.000101 0.000283 0.000443 1 1.260347 
2 0.008816 0.010916 
3 0.008665 0.010613 
9 1 0.002918 0.002842 0.003547 0.003649 0.000459 0.000611 0.859425 1 1.028744 
2 0.003997 0.004318 
3 0.003727 0.003787 
10 1 0.003854 0.003873 0.005064 0.005497 0.00131 0.001686 0.788287 1 1.085589 
2 0.006884 0.007821 
3 0.004454 0.004798 
11 1 0.003495 0.004181 0.002956 0.002932 0.000382 0.000885 0.973601 1 0.991881 
2 0.002719 0.002233 
3 0.002654 0.002383 
12 1 0.005725 0.007781 0.00374 0.004559 0.001405 0.002327 0.691884 1 1.219031 
2 0.002831 0.003527 
3 0.002664 0.002369 
13 1 0.005982 0.003306 0.003986 0.002672 0.001412 0.000451 0.278074 1 0.670334 
2 0.002968 0.002412 









Table 2: Luciferase assay results in H1299 
  






Replicate mock Ad5 mock Ad5 mock Ad5 T-test mock Ad5 
1 1 0.011149 0.021779 0.011925 0.019543 0.000632 0.001631 0.003527 1 1.638861 
2 0.011926 0.018913 
3 0.012698 0.017936 
2 1 0.004363 0.007918 0.004415 0.008168 0.00037 0.000391 0.000592 1 1.850152 
2 0.003989 0.008719 
3 0.004891 0.007866 
3 1 0.005662 0.001017 0.003334 0.001341 0.001652 0.00023 0.166419 1 0.402261 
2 0.001989 0.001485 
3 0.002351 0.001522 
4 1 0.001873 0.001378 0.006027 0.006582 0.003155 0.004456 0.892715 1 1.092024 
2 0.009514 0.012262 
3 0.006694 0.006105 
5 1 0.001878 0.001515 0.005659 0.006596 0.002987 0.004126 0.807592 1 1.165565 
2 0.009181 0.01162 
3 0.005919 0.006653 
6 1 0.002888 0.002618 0.004325 0.003837 0.002223 0.002166 0.835104 1 0.88729 
2 0.002622 0.002014 
3 0.007465 0.00688 
7 1 0.010439 0.003071 0.005619 0.003101 0.003418 0.000273 0.357636 1 0.551884 
2 0.003525 0.00345 
3 0.002894 0.002783 







2 0.003525 0.006617 
3 0.002894 0.002329 
9 1 0.008767 0.004831 0.004795 0.003433 0.002813 0.000996 0.553654 1 0.715904 
2 0.002991 0.002885 
3 0.002627 0.002583 
10 1 0.006976 0.008768 0.004221 0.004687 0.001962 0.002892 0.859463 1 1.110529 
2 0.002559 0.002892 
3 0.003127 0.002402 
11 1 0.006052 0.010757 0.004116 0.005483 0.001373 0.003741 0.65302 1 1.332033 
2 0.003013 0.003217 
3 0.003284 0.002476 
12 1 0.010421 0.009764 0.006928 0.005102 0.003306 0.003311 0.610381 1 0.73642 
2 0.007873 0.003152 
3 0.00249 0.00239 
Mean n=36 0.005582 0.00597 
       
 
 
 
 
